Stephen Salloway, MD, MS, is the founding Director of the Memory and Aging Program at Butler Hospital in Providence, Rhode Island. He is a Professor of Psychiatry and Human Behavior and Professor of Neurology at the Warren Alpert Medical School of Brown University. He received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University.
His research focuses on biomarker and drug development for prevention and early treatment of Alzheimer’s disease (AD). During his time at Brown, the Butler Hospital Memory and Aging Program (MAP) has become an internationally recognized center for clinical research in Alzheimer’s disease. The MAP has helped pioneer the use of PET ligands for amyloid and tau to study the evolution of AD pathophysiology in autosomal dominant and sporadic AD. The program has had a lead role in testing targeted treatments, such as BACE inhibitors and monoclonal antibodies, alone and in combination, to lower amyloid plaques and neurofibrillary tangles, as well as novel approaches, such as deep brain stimulation, to slow the progression of AD. The MAP is developing new strategies using genetic testing and brain imaging to recruit cognitively normal elderly at increased risk for AD for prevention studies.
Dr. Salloway has published more than 370 scientific articles and abstracts and has edited 3 books. These include lead authorship on pivotal trials in the New England Journal of Medicine, the Lancet, Nature, and JAMA Neurology. Dr. Salloway is a past president of the American Neuropsychiatric Association, a fellow of the American Academy of Neurology, and a member of the American Neurological Association. He serves on the Steering Committees for landmark NIH studies such as the Alzheimer’s Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer’s Network, and the Alzheimer’s Disease Clinical Trial Consortium. He is a scientific reviewer for the National Institutes of Health and for more than 30 journals, universities, and research foundations. Dr. Salloway lectures widely on prevention and early intervention for Alzheimer’s disease.
AD | Aging | Alzheimer's disease | drug development | prevention | biomarkers | molecular brain imaging | genetics | CADASIL |
Follow us on Twitter
Follow us on Facebook
| Daniels AJ, McDade E, Llibre-Guerra JJ, Xiong C, Perrin RJ, Ibanez L, Supnet-Bell C, Cruchaga C, Goate A, Renton AE, Benzinger TLS, Gordon BA, Hassenstab J, Karch C, Popp B, Levey A, Morris J, Buckles V, Allegri RF, Chrem P, Berman SB, Chhatwal JP, Farlow MR, Fox NC, Day GS, Ikeuchi T, Jucker M, Lee JH, Levin J, Lopera F, Takada L, Sosa AL, Martins R, Mori H, Noble JM, Salloway S, Huey E, Rosa-Neto P, Sánchez-Valle R, Schofield PR, Roh JH, Bateman RJ, Dominantly Inherited Alzheimer Network. "15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN." medRxiv : the preprint server for health sciences, 2024. |
| Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Suárez-Calvet M, Khachaturian AS, Mielke MM, Udeh-Momoh C, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Algeciras-Schimnich A, Aubrecht J, Braunstein JB, Hendrix J, Hu YH, Mattke S, Monane M, Reilly D, Somers E, Teunissen CE, Shobin E, Vanderstichele H, Weiner MW, Wilson D, Hansson O. "Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease." Nature reviews. Neurology, vol. 20, no. 7, 2024, pp. 426-439. |
| Chin NA, Dinsmore D, Gonzales T, Groves B, Johnson D, Napolitano J, Ropper A, Salloway S, Weiss L. "Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and Screening." New England Journal of Medicine, vol. 390, no. 10, 2024, pp. e22. |
| Chin NA, Dinsmore D, Gonzales T, Groves B, Houston S, Johnson D, Johnson D, Napolitano J, Ropper A, Salloway S, Sutherland R, Weiss L, Wheelock K. "Alzheimer's Disease - Managing Stages of Dementia." New England Journal of Medicine, vol. 390, no. 12, 2024, pp. e29. |
| Salloway S, Rowe C, Burns JM. "Are Blood Tests for Alzheimer Disease Ready for Prime Time?." JAMA, vol. 332, no. 15, 2024, pp. 1240-1241. |
| Howe MD, Britton KJ, Joyce HE, Menard W, Emrani S, Kunicki ZJ, Faust MA, Dawson BC, Riddle MC, Huey ED, Janelidze S, Hansson O, Salloway SP. "Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease." Alzheimer's research & therapy, vol. 16, no. 1, 2024, pp. 154. |
| Iaccarino L, Llibre-Guerra JJ, McDade E, Edwards L, Gordon B, Benzinger T, Hassenstab J, Kramer JH, Li Y, Miller BL, Miller Z, Morris JC, Mundada N, Perrin RJ, Rosen HJ, Soleimani-Meigooni D, Strom A, Tsoy E, Wang G, Xiong C, Allegri R, Chrem P, Vazquez S, Berman SB, Chhatwal J, Masters CL, Farlow MR, Jucker M, Levin J, Salloway S, Fox NC, Day GS, Gorno-Tempini ML, Boxer AL, La Joie R, Bateman R, Rabinovici GD. "Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease." Brain communications, vol. 6, no. 3, 2024, pp. fcae159. |
| Chen T, O'Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y, Patel D, von Rosenstiel P, von Hehn C, Salloway S, Hock C, Nitsch RM, Haeberlein SB, Sandrock A, Singhal P. "Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab." Alzheimer's & Dementia, vol. 20, no. 5, 2024, pp. 3406-3415. |
| Baker LD, Snyder HM, Espeland MA, Whitmer RA, Kivipelto M, Woolard N, Katula J, Papp KV, Ventrelle J, Graef S, Hill MA, Rushing S, Spell J, Lovato L, Felton D, Williams BJ, Ghadimi Nouran M, Raman R, Ngandu T, Solomon A, Wilmoth S, Cleveland ML, Williamson JD, Lambert KL, Tomaszewski Farias S, Day CE, Tangney CC, Gitelman DR, Matongo O, Reynolds T, Pavlik VN, Yu MM, Alexander AS, Elbein R, McDonald AM, Salloway S, Wing RR, Antkowiak S, Morris MC, Carrillo MC, U.S. POINTER Study Group. "Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER)." Alzheimer's & Dementia, vol. 20, no. 2, 2024, pp. 769-782. |
| Howe MD, Caruso MR, Manoochehri M, Kunicki ZJ, Emrani S, Rudolph JL, Huey ED, Salloway SP, Oh H, Alzheimer's Disease Neuroimaging Initiative. "Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis." Alzheimer's & Dementia, vol. 20, no. 10, 2024, pp. 7220-7231. |
| Howe MD, Caruso MR, Manoochehri M, Kunicki ZJ, Emrani S, Rudolph JL, Huey ED, Salloway SP, Oh H, Alzheimer’s Disease Neuroimaging Initiative. "Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis." medRxiv : the preprint server for health sciences, 2024. |
| Oxenford S, Ríos AS, Hollunder B, Neudorfer C, Boutet A, Elias GJB, Germann J, Loh A, Deeb W, Salvato B, Almeida L, Foote KD, Amaral R, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Sabbagh MN, Salloway S, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Anderson WS, Mari Z, Ponce FA, Lozano A, Neumann WJ, Al-Fatly B, Horn A. "WarpDrive: Improving spatial normalization using manual refinements." Medical image analysis, vol. 91, 2024, pp. 103041. |
| Cho H, Mundada NS, Apostolova LG, Carrillo MC, Shankar R, Amuiri AN, Zeltzer E, Windon CC, Soleimani-Meigooni DN, Tanner JA, Heath CL, Lesman-Segev OH, Aisen P, Eloyan A, Lee HS, Hammers DB, Kirby K, Dage JL, Fagan A, Foroud T, Grinberg LT, Jack CR, Kramer J, Kukull WA, Murray ME, Nudelman K, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski EJ, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Koeppe R, Iaccarino L, Dickerson BC, La Joie R, Rabinovici GD, LEADS Consortium. "Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)." Alzheimer's & Dementia, vol. 19 Suppl 9, no. Suppl 9, 2023, pp. S98-S114. |
| Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, Agus S, Sims JR, Bittner T, Carrillo MC, Fillit H, Masters CL, Salloway S, Aisen P, Weiner M, Vellas B, Gauthier S. "Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force." The journal of prevention of Alzheimer's disease, vol. 10, no. 3, 2023, pp. 418-425. |
| Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, Schindler SE, Snoddy C, Nudelman KNH, Faber KM, Foroud T, Aisen P, Griffin P, Grinberg LT, Iaccarino L, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga AW, Touroutoglou A, Vemuri P, Atri A, Beckett LA, Day GS, Graff-Radford NR, Duara R, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Womack KB, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG, LEADS Consortium. "Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study." Alzheimer's & Dementia, vol. 19 Suppl 9, no. Suppl 9, 2023, pp. S115-S125. |
| Griffin P, Apostolova L, Dickerson BC, Rabinovici G, Salloway S, Brandt K, Masdeu J, Hammers D, Raghuram S, Hall S, Carrillo MC. "Developments in understanding early onset Alzheimer's disease." Alzheimer's & Dementia, 2023. |
| Sims, John R., Zimmer, Jennifer A., Evans, Cynthia D., Lu, Ming, Ardayfio, Paul, Sparks, JonDavid, Wessels, Alette M., Shcherbinin, Sergey, Wang, Hong, Monkul Nery, Emel Serap, Collins, Emily C., Solomon, Paul, Salloway, Stephen, Apostolova, Liana G., Hansson, Oskar, Ritchie, Craig, Brooks, Dawn A., Mintun, Mark, Skovronsky, Daniel M., Abreu, Rafael, Agarwal, Pinky, Aggarwal, Puja, Agronin, Marc, Allen, Alison, Altamirano, Dario, Alva, Gustavo, Andersen, James, Anderson, Allan, Anderson, Donald, Arnold, Jennifer, Asada, Takashi, Aso, Yasuhiro, Atit, Vikram, Ayala, Ricardo, Badruddoja, Michael, Badzio-jagiello, Hanna, Bajacek, Michal, Barton, David, Bear, David, Benjamin, Sabrina, Bergeron, Richard, Bhatia, Perminder, Black, Sandra, Block, Allan, Bolouri, Mohammad, Bond, Wendy, Bouthillier, Jean, Brangman, Sharon, Brew, Bruce, Brisbin, Sarah, Brisken, Toby, Brodtmann, Amy, Brody, Mark, Brosch, Jared, Brown, Celia, Brownstone, Paul, Bukowczan, Sylwia, Burns, Jeffrey, Cabrera, Alicia, Capote, Horace, Carrasco, Angel, Cevallos Yepez, Jose, Chavez, Eric, Chertkow, Howard, Chyrchel-paszkiewicz, Urszula, Ciabarra, Anthony, Clemmons, Edward, Cohen, Daniel, Cohen, Robert, Cohen, Ian, Concha, Mauricio, Costell, Brian, Crimmins, Denis, Cruz-pagan, Yvette, Cueli, Adolfo, Cupelo, Robert, Czarnecki, Maciej, Darby, David, Dautzenberg, P.l.j., De Deyn, Peter, De La Gandara, Jose, Deck, Kenneth, Dibenedetto, David, Dibuono, Mark, Dinnerstein, Eric, Dirican, Ahmet, Dixit, Shanker, Dobryniewski, Jacek, Drake, Ryan, Drysdale, Peter, Duara, Ranjan, Duffy, John, Ellenbogen, Aaron, Faradji, Victor, Feinberg, Marc, Feldman, Robert, Fishman, Simon, Flitman, Stephen, Forchetti, Concetta, Fraga, Ivonne, Frank, Andrew, Frishberg, Benjamin, Fujigasaki, Hiroto, Fukase, Hiroyuki, Fumero, Ileana, Furihata, Kenichi, Galloway, Christopher, Gandhi, Rekha, George, Kristi, Germain, Marcel, Gitelman, Darren, Goetsch, Nicholas, Goldfarb, Danielle, Goldstein, Mark, Goldstick, Lawrence, Gonzalez Rojas, Yaneicy, Goodman, Ira, Greeley, David, Griffin, Carl, Grigsby, Eric, Grosz, Daniel, Hafner, Karl, Hart, David, Henein, Sam, Herskowitz, Brad, Higashi, Shinji, Higashi, Yasuto, Ho, Gilbert, Hodgson, Jonathan, Hohenberg, Mark, Hollenbeck, Larry, Holub, Richard, Hori, Tomokatsu, Hort, Jakub, Ilkowski, Jan, Ingram, K. Jennifer, Isaac, Mitchell, Ishikawa, Mitsunori, Janu, Lubos, Johnston, Mark, Julio, William, Justiz, William, Kaga, Tomotsugu, Kakigi, Tatsuya, Kalafer, Marvin, Kamijo, Mikiko, Kaplan, Jeffrey, Karathanos, Michael, Katayama, Sadao, Kaul, Siddharth, Keegan, Andrew, Kerwin, Diana, Khan, Uzma, Khan, Arifulla, Kimura, Noriyuki, Kirk, Gregory, Klodowska, Gabriela, Kowa, Hisatomo, Kutz, Christen, Kwentus, Joseph, Lai, Rosalyn, Lall, Ayesha, Lawrence, Mary, Lee, Elly, Leon, Ramon, Linker, Gary, Lisewski, Pawel, Liss, Jonathan, Liu, Collins, Losk, Scott, Lukaszyk, Ewelina, Lynch, Jennifer, Macfarlane, Stephen, Macsweeney, Josephine, Mannering, Nicholas, Markovic, Oto, Marks, Donald, Masdeu, Joseph, Matsui, Yutaka, Matsuishi, Kunitaka, Mcallister, Peter, Mcconnehey, Brock, Mcelveen, Alvin, Mcgill, Lora, Mecca, Adam, Mega, Michael, Mensah, Jason, Mickielewicz, Anatol, Minaeian, Artin, Mocherla, Bharat, Murphy, Cynthia, Murphy, Paul, Nagashima, Hirotaka, Nair, Anil, Nair, Malini, Nardandrea, John, Nash, Marshall, Nasreddine, Ziad, Nishida, Yoshihiko, Norton, Jeffrey, Nunez, Lazaro, Ochiai, Jun, Ohkubo, Takuya, Okamura, Yasuyuki, Okorie, Eugene, Olivera, Esteban, O'mahony, John, Omidvar, Omid, Ortiz-Cruz, Desiree, Osowa, Alexander, Papka, Michelle, Parker, Alicia, Patel, Paayal, Patel, Ashok, Patel, Meenakshi, Patry, Claude, Peckham, Elizabeth, Pfeffer, Michael, Pietras, Alison, Plopper, Michael, Porsteinsson, Anton, Poulin Robitaille, Raphael, Prins, Niels, Puente, Orlando, Ratajczak, Marcin, Rhee, Margaret, Ritter, Angela, Rodriguez, Ramon, Rodriguez Ables, Lilia, Rojas, Julio, Ross, Jeffrey, Royer, Paule, Rubin, Jay, Russell, David, Rutgers, Sterre Malou, Rutrick, Stephanie, Sadowski, Martin, Safirstein, Beth, Sagisaka, Takafumi, Scharre, Douglas, Schneider, Lon, Schreiber, Curtis, Schrift, Michael, Schulz, Paul, Schwartz, Harvey, Schwartzbard, Julie, Scott, John, Selem, Lissette, Sethi, Pramod, Sha, Sharon, Sharlin, Kenneth, Sharma, Sanjiv, Shiovitz, Thomas, Shiwach, Rajinder, Sladek, Martin, Sloan, Bart, Smith, Amanda, Solomon, Paul, Sorial, Ehab, Sosa, Evelio, Stedman, Mary, Steen, Susan, Stein, Lee, Stolyar, Arkadiy, Stoukides, John, Sudoh, Shinji, Sutton, James, Syed, Junaid, Szigeti, Kinga, Tachibana, Hisatsugu, Takahashi, Yuichi, Tateno, Amane, Taylor, James Dale, Taylor, Kelly, Tcheremissine, Oleg, Thebaud, Adly, Thein, Stephen, Thurman, Louise, Toenjes, Steven, Toji, Hiromasa, Toma, Misaki, Tran, Duc, Trueba, Pilar, Tsujimoto, Masashi, Turner, Raymond, Uchiyama, Akiyoshi, Ussorowska, Dorota, Vaishnavi, Sanjeev, Valor, Elena, Vandersluis, Joel, Vasquez, Alberto, Velez, Juan, Verghese, Cherian, Vodickova-borzova, Klaudia, Watson, David, Weidman, David, Weisman, David, White, Alexander, Willingham, Katherine, Winkel, Izabela, Winner, Paul, Winston, Jaron, Wolff, Adam, Yagi, Hideo, Yamamoto, Hideki, Yathiraj, Sanjay, Yoshiyama, Yasumasa, Zboch, Marzena, None, None. "Donanemab in Early Symptomatic Alzheimer Disease." JAMA, 2023. |
| Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging Initiative. "Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease." JAMA neurology, vol. 80, no. 12, 2023, pp. 1353-1363. |
| O'Connor A, Rice H, Barnes J, Ryan NS, Liu KY, Allegri RF, Berman S, Ringman JM, Cruchaga C, Farlow MR, Hassenstab J, Lee JH, Perrin RJ, Xiong C, Gordon B, Levey AI, Goate A, Graff-Radford N, Levin J, Jucker M, Benzinger T, McDade E, Mori H, Noble JM, Schofield PR, Martins RN, Salloway S, Chhatwal J, Morris JC, Bateman R, Howard R, Reeves S, Fox NC, Dominantly Inherited Alzheimer Network. "First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer's disease: the Dominantly Inherited Alzheimer's Network Study." Journal of Neurology, Neurosurgery & Psychiatry, vol. 94, no. 5, 2023, pp. 403-405. |
| Howe MD, Britton KJ, Joyce HE, Pappas GJ, Faust MA, Dawson BC, Riddle MC, Salloway SP. "Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval." The journal of prevention of Alzheimer's disease, vol. 10, no. 4, 2023, pp. 765-770. |
| Cummings, J., Apostolova, L., Rabinovici, G.D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R.C., Salloway, S. "Lecanemab: Appropriate Use Recommendations." The Journal of Prevention of Alzheimer's Disease, 2023. |
| Schultz SA, Shirzadi Z, Schultz AP, Liu L, Fitzpatrick CD, McDade E, Barthelemy NR, Renton A, Esposito B, Joseph-Mathurin N, Cruchaga C, Chen CD, Goate A, Allegri RF, Benzinger TLS, Berman S, Chui HC, Fagan AM, Farlow MR, Fox NC, Gordon BA, Day GS, Graff-Radford NR, Hassenstab JJ, Hanseeuw BJ, Hofmann A, Jack CR Jr, Jucker M, Karch CM, Koeppe RA, Lee JH, Levey AI, Levin J, Martins RN, Mori H, Morris JC, Noble J, Perrin RJ, Rosa-Neto P, Salloway SP, Sanchez-Valle R, Schofield PR, Xiong C, Johnson KA, Bateman RJ, Sperling RA, Chhatwal JP, Dominantly Inherited Alzheimer Network Investigators. "Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease." Aging Cell, 2023, pp. e13871. |
| Nudelman KNH, Jackson T, Rumbaugh M, Eloyan A, Abreu M, Dage JL, Snoddy C, Faber KM, Foroud T, Hammers DB, DIAN/DIAN-TU Clinical/Genetics Committee, Taurone A, Thangarajah M, Aisen P, Beckett L, Kramer J, Koeppe R, Kukull WA, Murray ME, Toga AW, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG, LEADS Consortium. "Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort." Alzheimer's & Dementia, vol. 19 Suppl 9, no. Suppl 9, 2023, pp. S64-S73. |
| McKay NS, Gordon BA, Hornbeck RC, Dincer A, Flores S, Keefe SJ, Joseph-Mathurin N, Jack CR, Koeppe R, Millar PR, Ances BM, Chen CD, Daniels A, Hobbs DA, Jackson K, Koudelis D, Massoumzadeh P, McCullough A, Nickels ML, Rahmani F, Swisher L, Wang Q, Allegri RF, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Day GS, Farlow MR, la Fougère C, Fox NC, Fulham M, Ghetti B, Graff-Radford N, Ikeuchi T, Klunk W, Lee JH, Levin J, Martins R, Masters CL, McConathy J, Mori H, Noble JM, Reischl G, Rowe C, Salloway S, Sanchez-Valle R, Schofield PR, Shimada H, Shoji M, Su Y, Suzuki K, Vöglein J, Yakushev I, Cruchaga C, Hassenstab J, Karch C, McDade E, Perrin RJ, Xiong C, Morris JC, Bateman RJ, Benzinger TLS, Dominantly Inherited Alzheimer Network. "Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)." Nature Neuroscience, vol. 26, no. 8, 2023, pp. 1449-1460. |
| Howe MD, Rabinovici GD, Salloway SP. "Real-World Application of Anti-β-Amyloid Monoclonal Antibodies: Untangling Eligibility." Neurology, vol. 101, no. 19, 2023, pp. 811-812. |
| Thompson LI, Kunicki ZJ, Emrani S, Strenger J, De Vito AN, Britton KJ, Dion C, Harrington KD, Roque N, Salloway S, Sliwinski MJ, Correia S, Jones RN. "Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults." Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol. 15, no. 4, 2023, pp. e12500. |
| Nemes S, Logan PE, Manchella MK, Mundada NS, La Joie R, Polsinelli AJ, Hammers DB, Koeppe RA, Foroud TM, Nudelman KN, Eloyan A, Iaccarino L, Dorsant-Ardón V, Taurone A, Thangarajah M, Dage JL, Aisen P, Grinberg LT, Jack CR Jr, Kramer J, Kukull WA, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Womack KB, Wolk DA, Rabinovici GD, Carrillo MC, Dickerson BC, Apostolova LG, LEADS Consortium. "Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease." Alzheimer's & Dementia, vol. 19 Suppl 9, no. Suppl 9, 2023, pp. S49-S63. |
| Lee AKW, Collier MK, Thompson LI, Popescu D, Arthur E, Correia S, Salloway SP, Alber J. "The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry." The journal of prevention of Alzheimer's disease, vol. 10, no. 2, 2023, pp. 152-161. |
| Touroutoglou A, Katsumi Y, Brickhouse M, Zaitsev A, Eckbo R, Aisen P, Beckett L, Dage JL, Eloyan A, Foroud T, Ghetti B, Griffin P, Hammers D, Jack CR Jr, Kramer JH, Iaccarino L, Joie R, Mundada NS, Koeppe R, Kukull WA, Murray ME, Nudelman K, Polsinelli AJ, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Carrillo MC, Rabinovici GD, Apostolova LG, Dickerson BC, LEADS Consortium. "The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort." Alzheimer's & Dementia, vol. 19 Suppl 9, no. Suppl 9, 2023, pp. S74-S88. |
| Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS, GRADUATE I and II Investigators and the Gantenerumab Study Group. "Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease." New England Journal of Medicine, vol. 389, no. 20, 2023, pp. 1862-1876. |
| Eloyan A, Thangarajah M, An N, Borowski BJ, Reddy AL, Aisen P, Dage JL, Foroud T, Ghetti B, Griffin P, Hammers D, Iaccarino L, Jack CR Jr, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Beckett L, Gao S, Carrillo MC, Rabinovici G, Apostolova LG, Dickerson B, Vemuri P, LEADS Consortium. "White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS)." Alzheimer's & Dementia, vol. 19 Suppl 9, no. Suppl 9, 2023, pp. S89-S97. |
| Thompson LI, Harrington KD, Roque N, Strenger J, Correia S, Jones RN, Salloway S, Sliwinski MJ. "A highly feasible, reliable, and fully remote protocol for mobile app-based cognitive assessment in cognitively healthy older adults." Alzheimer's & dementia (Amsterdam, Netherlands), vol. 14, no. 1, 2022, pp. e12283. |
| Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, Sabbagh M, Selkoe D, Weiner M, Salloway S. "Aducanumab: Appropriate Use Recommendations Update." The journal of prevention of Alzheimer's disease, vol. 9, no. 2, 2022, pp. 221-230. |
| Rhodus EK, Aisen P, Grill JD, Rentz DM, Petersen RC, Sperling RA, Salloway SP, Pierce D, Raman R. "Alzheimer's Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer's Clinical Trial Consortium Sites." The journal of prevention of Alzheimer's disease, vol. 9, no. 4, 2022, pp. 665-671. |
| Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, Park E, Wang G, Preboske GM, Wang Q, Gordon BA, Chen CD, Flores S, Aggarwal NT, Berman SB, Bird TD, Black SE, Borowski B, Brooks WS, Chhatwal JP, Clarnette R, Cruchaga C, Fagan AM, Farlow M, Fox NC, Gauthier S, Hassenstab J, Hobbs DA, Holdridge KC, Honig LS, Hornbeck RC, Hsiung GR, Jack CR Jr, Jimenez-Velazquez IZ, Jucker M, Klein G, Levin J, Mancini M, Masellis M, McKay NS, Mummery CJ, Ringman JM, Shimada H, Snider BJ, Suzuki K, Wallon D, Xiong C, Yaari R, McDade E, Perrin RJ, Bateman RJ, Salloway SP, Benzinger TLS, Clifford DB, Dominantly Inherited Alzheimer Network Trials Unit. "Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease." Annals of neurology, vol. 92, no. 5, 2022, pp. 729-744. |
| Lim YY, Maruff P, Barthélemy NR, Goate A, Hassenstab J, Sato C, Fagan AM, Benzinger TLS, Xiong C, Cruchaga C, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield PR, Morris JC, Bateman RJ, McDade E, Dominantly Inherited Alzheimer Network. "Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease." JAMA neurology, vol. 79, no. 3, 2022, pp. 261-270. |
| Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS, Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, Fagan AM, Farlow M, Fox NC, Ghetti B, Goate AM, Gordon BA, Graff-Radford N, Day GS, Hassenstab J, Ikeuchi T, Jack CR, Jagust WJ, Jucker M, Levin J, Massoumzadeh P, Masters CL, Martins R, McDade E, Mori H, Noble JM, Petersen RC, Ringman JM, Salloway S, Saykin AJ, Schofield PR, Shaw LM, Toga AW, Trojanowski JQ, Vöglein J, Weninger S, Bateman RJ, Buckles VD. "Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology." Brain, vol. 145, no. 10, 2022, pp. 3594-3607. |
| Aschenbrenner AJ, Hassenstab J, Wang G, Li Y, Xiong C, McDade E, Clifford DB, Salloway S, Farlow M, Yaari R, Cheng EYJ, Holdridge KC, Mummery CJ, Masters CL, Hsiung GY, Surti G, Day GS, Weintraub S, Honig LS, Galvin JE, Ringman JM, Brooks WS, Fox NC, Snyder PJ, Suzuki K, Shimada H, Gräber S, Bateman RJ. "Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials." Frontiers in Aging Neuroscience, vol. 14, 2022, pp. 883131. |
| Luckett PH, Chen C, Gordon BA, Wisch J, Berman SB, Chhatwal JP, Cruchaga C, Fagan AM, Farlow MR, Fox NC, Jucker M, Levin J, Masters CL, Mori H, Noble JM, Salloway S, Schofield PR, Brickman AM, Brooks WS, Cash DM, Fulham MJ, Ghetti B, Jack CR Jr, Vöglein J, Klunk WE, Koeppe R, Su Y, Weiner M, Wang Q, Marcus D, Koudelis D, Joseph-Mathurin N, Cash L, Hornbeck R, Xiong C, Perrin RJ, Karch CM, Hassenstab J, McDade E, Morris JC, Benzinger TLS, Bateman RJ, Ances BM, Dominantly Inherited Alzheimer Network (DIAN). "Biomarker clustering in autosomal dominant Alzheimer's disease." Alzheimer's & Dementia, 2022. |
| Bateman RJ, Cummings J, Schobel S, Salloway S, Vellas B, Boada M, Black SE, Blennow K, Fontoura P, Klein G, Assunção SS, Smith J, Doody RS. "Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease." Alzheimer's research & therapy, vol. 14, no. 1, 2022, pp. 178. |
| Gold D, Wisialowski C, Piryatinsky I, Malloy P, Correia S, Salloway S, Klinge P, Gaudet CE, Niermeyer M, Lee A. "Longitudinal post-shunt outcomes in idiopathic normal pressure hydrocephalus with and without comorbid Alzheimer's disease." Journal of the International Neuropsychological Society, 2022, pp. 1-12. |
| Ríos AS, Oxenford S, Neudorfer C, Butenko K, Li N, Rajamani N, Boutet A, Elias GJB, Germann J, Loh A, Deeb W, Wang F, Setsompop K, Salvato B, Almeida LB, Foote KD, Amaral R, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Salloway S, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Anderson WS, Mari Z, Ponce FA, Lozano AM, Horn A. "Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease." Nature Communications, vol. 13, no. 1, 2022, pp. 7707. |
| Vöglein J, Franzmeier N, Morris JC, Dieterich M, McDade E, Simons M, Preische O, Hofmann A, Hassenstab J, Benzinger TL, Fagan A, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal JP, Salloway S, Xiong C, Karch CM, Cairns N, Perrin RJ, Day G, Martins R, Sanchez-Valle R, Mori H, Shimada H, Ikeuchi T, Suzuki K, Schofield PR, Masters CL, Goate A, Buckles V, Fox NC, Chrem P, Allegri R, Ringman JM, Yakushev I, Laske C, Jucker M, Höglinger G, Bateman RJ, Danek A, Levin J, Dominantly Inherited Alzheimer Network. "Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease." Alzheimer's & Dementia, 2022. |
| Millar PR, Luckett PH, Gordon BA, Benzinger TLS, Schindler SE, Fagan AM, Cruchaga C, Bateman RJ, Allegri R, Jucker M, Lee JH, Mori H, Salloway SP, Yakushev I, Morris JC, Ances BM, Dominantly Inherited Alzheimer Network. "Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease." NeuroImage, vol. 256, 2022, pp. 119228. |
| Alber J, Popescu D, Thompson LI, Tonini GM, Arthur E, Oh H, Correia S, Salloway SP, Lee AK. "Safety and Tolerability of APOE Genotyping and Disclosure in Cognitively Normal Volunteers From the Butler Alzheimer's Prevention Registry." Journal of Geriatric Psychiatry and Neurology, vol. 35, no. 3, 2022, pp. 293-301. |
| Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE. "The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease." Alzheimer's & Dementia, vol. 18, no. 12, 2022, pp. 2669-2686. |
| Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ, Dominantly Inherited Alzheimer Network–Trials Unit. "A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease." Nature Medicine, vol. 27, no. 7, 2021, pp. 1187-1196. |
| Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Presseau E, Villeneuve S, Alzheimer’s Disease Neuroimaging Initiative (ADNI)., Dominantly Inherited Alzheimer Network (DIAN) Study Group., Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease (PREVENT-AD) Research Group. "Accelerated functional brain aging in pre-clinical familial Alzheimer's disease." Nature Communications, vol. 12, no. 1, 2021, pp. 5346. |
| O'Shea, Deirdre M., Thomas, Kelsey R., Asken, Breton, Lee, Athene K.W., Davis, Jennifer D., Malloy, Paul F., Salloway, Stephen P., Correia, Stephen, None, None. "Adding cognition to AT(N) models improves prediction of cognitive and functional decline." Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol. 13, no. 1, 2021. |
| Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. "Aducanumab produced a clinically meaningful benefit in association with amyloid lowering." Alzheimer's research & therapy, vol. 13, no. 1, 2021, pp. 98. |
| Salloway S, Cummings J. "Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease." Neurology, vol. 97, no. 11, 2021, pp. 543-544. |
| Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. "Aducanumab: Appropriate Use Recommendations." The journal of prevention of Alzheimer's disease, vol. 8, no. 4, 2021, pp. 398-410. |
| Lu M, Pontecorvo MJ, Devous MD Sr, Arora AK, Galante N, McGeehan A, Devadanam C, Salloway SP, Doraiswamy PM, Curtis C, Truocchio SP, Flitter M, Locascio T, Devine M, Zimmer JA, Fleisher AS, Mintun MA, AVID Collaborators. "Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials." JAMA neurology, vol. 78, no. 4, 2021, pp. 445-453. |
| Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, Wang G, Singhal P, Budd Haeberlein S, Smirnakis K. "Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease." JAMA neurology, 2021. |
| Montal V, Vilaplana E, Pegueroles J, Bejanin A, Alcolea D, Carmona-Iragui M, Clarimón J, Levin J, Cruchaga C, Graff-Radford NR, Noble JM, Lee JH, Allegri R, Karch CM, Laske C, Schofield PR, Salloway S, Ances B, Benzinger T, McDale E, Bateman R, Blesa R, Sánchez-Valle R, Lleó A, Fortea J, Dominantly Inherited Alzheimer Network (DIAN). "Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease." Alzheimer's & Dementia, vol. 17, no. 4, 2021, pp. 618-628. |
| Germann J, Elias GJB, Boutet A, Narang K, Neudorfer C, Horn A, Loh A, Deeb W, Salvato B, Almeida L, Foote KD, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Salloway S, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Lozano AM. "Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease." Alzheimer's & Dementia, vol. 17, no. 5, 2021, pp. 777-787. |
| Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH. "Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group." The Lancet Neurology, vol. 20, no. 6, 2021, pp. 484-496. |
| Fagan AM, Henson RL, Li Y, Boerwinkle AH, Xiong C, Bateman RJ, Goate A, Ances BM, Doran E, Christian BT, Lai F, Rosas HD, Schupf N, Krinsky-McHale S, Silverman W, Lee JH, Klunk WE, Handen BL, Allegri RF, Chhatwal JP, Day GS, Graff-Radford NR, Jucker M, Levin J, Martins RN, Masters CL, Mori H, Mummery CJ, Niimi Y, Ringman JM, Salloway S, Schofield PR, Shoji M, Lott IT, Alzheimer's Biomarker Consortium–Down Syndrome., Dominantly Inherited Alzheimer Network. "Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study." The Lancet Neurology, vol. 20, no. 8, 2021, pp. 615-626. |
| Kunicki, Zachary J., Gaudiano, Brandon A., Miller, Ivan W., Tremont, Geoffrey, Salloway, Stephen, Darling, Ellen, Broughton, Monica K., Kraines, Morganne A., Hoopes, Ryan, Epstein-Lubow, Gary. "Differences in Burden Severity in Adult-Child Family Caregivers and Spousal Caregivers of Persons with Dementia." Journal of Gerontological Social Work, vol. 64, no. 5, 2021, pp. 518-532. |
| Buckles VD, Xiong C, Bateman RJ, Hassenstab J, Allegri R, Berman SB, Chhatwal JP, Danek A, Fagan AM, Ghetti B, Goate A, Graff-Radford N, Jucker M, Levin J, Marcus DS, Masters CL, McCue L, McDade E, Mori H, Moulder KL, Noble JM, Paumier K, Preische O, Ringman JM, Fox NC, Salloway S, Schofield PR, Martins R, Vöglein J, Morris JC, Dominantly Inherited Alzheimer's Network. "Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease." Alzheimer's & Dementia, 2021. |
| Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. "Donanemab in Early Alzheimer's Disease." New England Journal of Medicine, vol. 384, no. 18, 2021, pp. 1691-1704. |
| McLaughlin NCR, Dougherty DD, Eskandar E, Ward H, Foote KD, Malone DA, Machado A, Wong W, Sedrak M, Goodman W, Kopell BH, Issa F, Shields DC, Abulseoud OA, Lee K, Frye MA, Widge AS, Deckersbach T, Okun MS, Bowers D, Bauer RM, Mason D, Kubu CS, Bernstein I, Lapidus K, Rosenthal DL, Jenkins RL, Read C, Malloy PF, Salloway S, Strong DR, Jones RN, Rasmussen SA, Greenberg BD. "Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design." Contemporary Clinical Trials Communications, vol. 22, 2021, pp. 100785. |
| Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Sperling RA, Aisen PS, Rafii MS, Rissman RA. "Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial." Alzheimer's & dementia (Amsterdam, Netherlands), vol. 13, no. 1, 2021, pp. e12199. |
| Joseph-Mathurin N, Wang G, Kantarci K, Jack CR Jr, McDade E, Hassenstab J, Blazey TM, Gordon BA, Su Y, Chen G, Massoumzadeh P, Hornbeck RC, Allegri RF, Ances BM, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Chui HC, Correia S, Cruchaga C, Farlow MR, Fox NC, Fulham M, Ghetti B, Graff-Radford NR, Johnson KA, Karch CM, Laske C, Lee AKW, Levin J, Masters CL, Noble JM, O'Connor A, Perrin RJ, Preboske GM, Ringman JM, Rowe CC, Salloway S, Saykin AJ, Schofield PR, Shimada H, Shoji M, Suzuki K, Villemagne VL, Xiong C, Yakushev I, Morris JC, Bateman RJ, Benzinger TLS, Dominantly Inherited Alzheimer Network. "Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease." Neurology, vol. 96, no. 12, 2021, pp. e1632-e1645. |
| Neudorfer C, Elias GJB, Jakobs M, Boutet A, Germann J, Narang K, Loh A, Paff M, Horn A, Kucharczyk W, Deeb W, Salvato B, Almeida L, Foote KD, Rosenberg PB, Tang-Wai DF, Anderson WS, Mari Z, Ponce FA, Wolk DA, Burke AD, Salloway S, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Lozano AM. "Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation." Brain, vol. 144, no. 9, 2021, pp. 2837-2851. |
| Luckett PH, et al. "Modeling autosomal dominant Alzheimer's disease with machine learning." Alzheimer's & Dementia, 2021. |
| Keret O, Staffaroni AM, Ringman JM, Cobigo Y, Goh SM, Wolf A, Allen IE, Salloway S, Chhatwal J, Brickman AM, Reyes-Dumeyer D, Bateman RJ, Benzinger TLS, Morris JC, Ances BM, Joseph-Mathurin N, Perrin RJ, Gordon BA, Levin J, Vöglein J, Jucker M, la Fougère C, Martins RN, Sohrabi HR, Taddei K, Villemagne VL, Schofield PR, Brooks WS, Fulham M, Masters CL, Ghetti B, Saykin AJ, Jack CR, Graff-Radford NR, Weiner M, Cash DM, Allegri RF, Chrem P, Yi S, Miller BL, Rabinovici GD, Rosen HJ, Dominantly Inherited Alzheimer Network. "Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease." Alzheimer's & dementia (Amsterdam, Netherlands), vol. 13, no. 1, 2021, pp. e12197. |
| Ewers M, Luan Y, Frontzkowski L, Neitzel J, Rubinski A, Dichgans M, Hassenstab J, Gordon BA, Chhatwal JP, Levin J, Schofield P, Benzinger TLS, Morris JC, Goate A, Karch CM, Fagan AM, McDade E, Allegri R, Berman S, Chui H, Cruchaga C, Farlow M, Graff-Radford N, Jucker M, Lee JH, Martins RN, Mori H, Perrin R, Xiong C, Rossor M, Fox NC, O'Connor A, Salloway S, Danek A, Buerger K, Bateman RJ, Habeck C, Stern Y, Franzmeier N, Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer Network. "Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease." Brain, 2021. |
| Barthélemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, Morris JC, Karch CM, Xiong C, Allegri R, Mendez PC, Berman SB, Ikeuchi T, Mori H, Shimada H, Shoji M, Suzuki K, Noble J, Farlow M, Chhatwal J, Graff-Radford NR, Salloway S, Schofield PR, Masters CL, Martins RN, O'Connor A, Fox NC, Levin J, Jucker M, Gabelle A, Lehmann S, Sato C, Bateman RJ, McDade E, Dominantly Inherited Alzheimer Network. "A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease." Nature Medicine, vol. 26, no. 3, 2020, pp. 398-407. |
| None, None, None, None, None, None. "Accelerating Preclinical Alzheimer’s Clinical Trials through a Trial-Ready Cohort with Diverse Representation." The journal of prevention of Alzheimer's disease, 2020. |
| Salloway SP, Sevingy J, Budur K, Pederson JT, DeMattos RB, Von Rosenstiel P, Paez A, Evans R, Weber CJ, Hendrix JA, Worley S, Bain LJ, Carrillo MC. "Advancing combination therapy for Alzheimer's disease." Alzheimer's & dementia (New York, N. Y.), vol. 6, no. 1, 2020, pp. e12073. |
| Castillo-Barnes D, Su L, Ramírez J, Salas-Gonzalez D, Martinez-Murcia FJ, Illan IA, Segovia F, Ortiz A, Cruchaga C, Farlow MR, Xiong C, Graff-Radford NR, Schofield PR, Masters CL, Salloway S, Jucker M, Mori H, Levin J, Gorriz JM, Dominantly Inherited Alzheimer Network (DIAN). "Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning." An international journal on information fusion, vol. 58, 2020, pp. 153-167. |
| Aschenbrenner AJ, James BD, McDade E, Wang G, Lim YY, Benzinger TLS, Cruchaga C, Goate A, Xiong C, Perrin R, Buckles V, Allegri R, Berman SB, Chhatwal JP, Fagan A, Farlow M, O'Connor A, Ghetti B, Graff-Radford N, Goldman J, Gräber S, Karch CM, Lee JH, Levin J, Martins RN, Masters C, Mori H, Noble J, Salloway S, Schofield P, Morris JC, Bateman RJ, Hassenstab J, Dominantly Inherited Alzheimer Network. "Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)." Alzheimer's & Dementia, vol. 16, no. 1, 2020, pp. 219-228. |
| Dincer A, Gordon BA, Hari-Raj A, Keefe SJ, Flores S, McKay NS, Paulick AM, Shady Lewis KE, Feldman RL, Hornbeck RC, Allegri R, Ances BM, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Farlow MR, la Fougère C, Fox NC, Fulham MJ, Jack CR Jr, Joseph-Mathurin N, Karch CM, Lee A, Levin J, Masters CL, McDade EM, Oh H, Perrin RJ, Raji C, Salloway SP, Schofield PR, Su Y, Villemagne VL, Wang Q, Weiner MW, Xiong C, Yakushev I, Morris JC, Bateman RJ, L S Benzinger T, Dominantly Inherited Alzheimer Network DIAN. "Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease." NeuroImage. Clinical, vol. 28, 2020, pp. 102491. |
| Alber J, Goldfarb D, Thompson LI, Arthur E, Hernandez K, Cheng D, DeBuc DC, Cordeiro F, Provetti-Cunha L, den Haan J, Van Stavern GP, Salloway SP, Sinoff S, Snyder PJ. "Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward." Alzheimer's & Dementia, vol. 16, no. 1, 2020, pp. 229-243. |
| Alber J, Maruff P, Santos CY, Ott BR, Salloway SP, Yoo DC, Noto RB, Thompson LI, Goldfarb D, Arthur E, Song A, Snyder PJ. "Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay interval." Alzheimer's research & therapy, vol. 12, no. 1, 2020, pp. 31. |
| Lee AKW, Correia S, Salloway SP. "Editorial: Accelerating Preclinical Alzheimer's Clinical Trials through a Trial-Ready Cohort with Diverse Representation." The journal of prevention of Alzheimer's disease, vol. 7, no. 4, 2020, pp. 204-205. |
| Niermeyer M, Gaudet C, Malloy P, Piryatinsky I, Salloway S, Klinge P, Lee A. "Frontal Behavior Syndromes in Idiopathic Normal Pressure Hydrocephalus as a Function of Alzheimer's Disease Biomarker Status." Journal of the International Neuropsychological Society, vol. 26, no. 9, 2020, pp. 1-11. |
| Bruchhage MMK, Correia S, Malloy P, Salloway S, Deoni S. "Machine Learning Classification Identifies Cerebellar Contributions to Early and Moderate Cognitive Decline in Alzheimer's Disease." Frontiers in Aging Neuroscience, vol. 12, 2020, pp. 524024. |
| Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, Aldea P, Flitter M, Locascio T, Devine M, Siderowf A, Beach TG, Montine TJ, Serrano GE, Curtis C, Perrin A, Salloway S, Daniel M, Wellman C, Joshi AD, Irwin DJ, Lowe VJ, Seeley WW, Ikonomovic MD, Masdeu JC, Kennedy I, Harris T, Navitsky M, Southekal S, Mintun MA, A16 Study Investigators. "Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes." JAMA neurology, 2020. |
| Franzmeier N, Koutsouleris N, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Duering M, Dichgans M, Levin J, Gordon BA, Lim YY, Masters CL, Rossor M, Fox NC, O'Connor A, Chhatwal J, Salloway S, Danek A, Hassenstab J, Schofield PR, Morris JC, Bateman RJ, Alzheimer's disease neuroimaging initiative (ADNI)., Dominantly Inherited Alzheimer Network (DIAN)., Ewers M. "Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning." Alzheimer's & Dementia, vol. 16, no. 3, 2020, pp. 501-511. |
| Schultz SA, Strain JF, Adedokun A, Wang Q, Preische O, Kuhle J, Flores S, Keefe S, Dincer A, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal J, Cruchaga C, Ewers M, Fox NN, Ghetti B, Goate A, Graff-Radford NR, Hassenstab JJ, Hornbeck R, Jack C Jr, Johnson K, Joseph-Mathurin N, Karch CM, Koeppe RA, Lee AKW, Levin J, Masters C, McDade E, Perrin RJ, Rowe CC, Salloway S, Saykin AJ, Sperling R, Su Y, Villemagne VL, Vöglein J, Weiner M, Xiong C, Fagan AM, Morris JC, Bateman RJ, Benzinger TLS, Jucker M, Gordon BA, Dominantly Inherited Alzheimer Network. "Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease." Neurobiology of disease, vol. 142, 2020, pp. 104960. |
| Finsterwalder S, et al. "Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients." Alzheimer's & Dementia, vol. 16, no. 11, 2020, pp. 1504-1514. |
| Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, Sims J, Sperling RA, Vellas B. "The Future of Anti-Amyloid Trials." The journal of prevention of Alzheimer's disease, vol. 7, no. 3, 2020, pp. 146-151. |
| Dubbelman MA, Verrijp M, Facal D, Sánchez-Benavides G, Brown LJE, van der Flier WM, Jokinen H, Lee A, Leroi I, Lojo-Seoane C, Milošević V, Molinuevo JL, Pereiro Rozas AX, Ritchie C, Salloway S, Stringer G, Zygouris S, Dubois B, Epelbaum S, Scheltens P, Sikkes SAM. "The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries." Alzheimer's & dementia (Amsterdam, Netherlands), vol. 12, no. 1, 2020, pp. e12021. |
| Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, Salloway S, Doraiswamy PM, Southekal S, Arora AK, McGeehan A, Lim NC, Xiong H, Truocchio SP, Joshi AD, Shcherbinin S, Teske B, Fleisher AS, Mintun MA. "A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia." Brain, vol. 142, no. 6, 2019, pp. 1723-1735. |
| Dube U, Del-Aguila JL, Li Z, Budde JP, Jiang S, Hsu S, Ibanez L, Fernandez MV, Farias F, Norton J, Gentsch J, Wang F, Dominantly Inherited Alzheimer Network (DIAN)., Salloway S, Masters CL, Lee JH, Graff-Radford NR, Chhatwal JP, Bateman RJ, Morris JC, Karch CM, Harari O, Cruchaga C. "An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations." Nature Neuroscience, vol. 22, no. 11, 2019, pp. 1903-1912. |
| Shoamanesh A, Salloway S, Kase CS. "Are lobar microbleeds of diagnostic value in the community?." Neurology, vol. 92, no. 3, 2019, pp. 121-122. |
| Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, Benzinger TLS, Hassenstab J, Wang G, Allegri R, Berman SB, Chhatwal J, Farlow MR, Holtzman DM, Jucker M, Levin J, Noble JM, Salloway S, Schofield P, Karch C, Fox NC, Xiong C, Bateman RJ, McDade E. "Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease." JAMA Network Open, vol. 2, no. 12, 2019, pp. e1917126. |
| Vöglein J, Paumier K, Jucker M, Preische O, McDade E, Hassenstab J, Benzinger TL, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal J, Salloway S, Xiong C, Karch CM, Cairns N, Mori H, Schofield PR, Masters CL, Goate A, Buckles V, Fox N, Rossor M, Chrem P, Allegri R, Ringman JM, Höglinger G, Steiner H, Dieterich M, Haass C, Laske C, Morris JC, Bateman RJ, Danek A, Levin J. "Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease." Brain, 2019. |
| Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P. "Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force." The journal of prevention of Alzheimer's disease, vol. 6, no. 3, 2019, pp. 164-168. |
| Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS. "Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies." Alzheimer's & dementia (Amsterdam, Netherlands), vol. 11, 2019, pp. 180-190. |
| Asken BM, Thomas KR, Lee A, Davis JD, Malloy PF, Salloway SP, Correia S. "Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes." Journal of the International Neuropsychological Society, vol. 26, no. 5, 2019, pp. 464-479. |
| Deeb W, Salvato B, Almeida L, Foote KD, Amaral R, Germann J, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Salloway S, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Lozano AM, Okun MS. "Fornix-Region Deep Brain Stimulation-Induced Memory Flashbacks in Alzheimer's Disease." New England Journal of Medicine, vol. 381, no. 8, 2019, pp. 783-785. |
| Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B. "Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report." The journal of prevention of Alzheimer's disease, vol. 6, no. 3, 2019, pp. 169-173. |
| Wolk D, Salloway S, Dickerson B. "Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test." JAMA, vol. 321, no. 23, 2019, pp. 2289-2291. |
| Vöglein J, Noachtar S, McDade E, Quaid KA, Salloway S, Ghetti B, Noble J, Berman S, Chhatwal J, Mori H, Fox N, Allegri R, Masters CL, Buckles V, Ringman JM, Rossor M, Schofield PR, Sperling R, Jucker M, Laske C, Paumier K, Morris JC, Bateman RJ, Levin J, Danek A, Dominantly Inherited Alzheimer Network. "Seizures as an early symptom of autosomal dominant Alzheimer's disease." Neurobiology of aging, vol. 76, 2019, pp. 18-23. |
| Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M, Dominantly Inherited Alzheimer Network. "Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease." Nature Medicine, vol. 25, no. 2, 2019, pp. 277-283. |
| Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M. "The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease." Molecular Psychiatry, 2019. |
| Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R. "Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)." Alzheimer's research & therapy, vol. 10, no. 1, 2018, pp. 96. |
| Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, Schindler S, Carrillo MC, Hendrix JA, Ross A, Illes J, Ramus C, Fifer S. "Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease." Alzheimer's & Dementia, vol. 14, no. 11, 2018, pp. 1505-1521. |
| Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR, ELN115727-301/302 Investigator Group. "Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab." Neurology, vol. 90, no. 10, 2018, pp. e877-e886. |
| Brashear HR, Ketter N, Bogert J, Di J, Salloway SP, Sperling R. "Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies." Journal of Alzheimer's disease : JAD, 2018. |
| Leoutsakos JS, Yan H, Anderson WS, Asaad WF, Baltuch G, Burke A, Chakravarty MM, Drake KE, Foote KD, Fosdick L, Giacobbe P, Mari Z, McAndrews MP, Munro CA, Oh ES, Okun MS, Pendergrass JC, Ponce FA, Rosenberg PB, Sabbagh MN, Salloway S, Tang-Wai DF, Targum SD, Wolk D, Lozano AM, Smith GS, Lyketsos CG. "Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation." Journal of Alzheimer's disease : JAD, vol. 64, no. 2, 2018, pp. 597-606. |
| Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, Morris JC, Maruff P, Bateman RJ, Dominantly Inherited Alzheimer Network. "Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease." Annals of neurology, vol. 84, no. 3, 2018, pp. 424-435. |
| Salloway S. "Improving Evaluation of Patients With Cognitive Impairment With Amyloid Positron Emission Tomography." JAMA neurology, 2018. |
| Ikonomovic MD, Fantoni ER, Farrar G, Salloway S. "Infrequent false positive [<sup>18</sup>F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques." Alzheimer's research & therapy, vol. 10, no. 1, 2018, pp. 60. |
| Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Perneczky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M. "Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease." Brain, vol. 4, 2018, pp. 1186-1200. |
| Salloway SP, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, Rofael H, Ketter N, Wang D, Liu E, Carr S, Black RS, Brashear HR. "Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study." Journal of Alzheimer's disease : JAD, vol. 64, no. 3, 2018, pp. 689-707. |
| Salloway S, Marshall GA, Lu M, Brashear HR. "Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-To-Moderate Alzheimer's Disease: A Phase 2, Open Label Extension Study." Current Alzheimer research, 2018. |
| McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ, Dominantly Inherited Alzheimer Network. "Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease." Neurology, 2018. |
| Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, Jack C Jr, Ances BM, Ringman JM, Marcus DS, Ghetti B, Farlow MR, Danek A, Levin J, Yakushev I, Laske C, Koeppe RA, Galasko DR, Xiong C, Masters CL, Schofield PR, Kinnunen KM, Salloway S, Martins RN, McDade E, Cairns NJ, Buckles VD, Morris JC, Bateman R, Sperling RA, Dominantly Inherited Alzheimer Network. "Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing." Brain, 2018. |
| Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, Leung KK, Cardoso MJ, Modat M, Malone IB, Morris JC, Bateman RJ, Marcus DS, Goate A, Salloway SP, Correia S, Sperling RA, Chhatwal JP, Mayeux RP, Brickman AM, Martins RN, Farlow MR, Ghetti B, Saykin AJ, Jack CR Jr., Schofield PR, McDade E, Weiner MW, Ringman JM, Thompson PM, Masters CL, Rowe CC, Rossor MN, Ourselin S, Fox NC, Dominantly Inherited Alzheimer Network (DIAN). "Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study." Alzheimer's & Dementia, vol. 14, no. 1, 2018, pp. 43-53. |
| Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C, Dominantly Inherited Alzheimer Network (DIAN). "Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease." Alzheimer's & Dementia, 2018. |
| Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS. "Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study." The Lancet Neurology, vol. 17, no. 3, 2018, pp. 241-250. |
| Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B. "What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force." The journal of prevention of Alzheimer's disease, vol. 5, no. 3, 2018, pp. 171-174. |
| Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M. "White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease." Brain, vol. 141, no. 10, 2018, pp. 3065-3080. |
| Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM, Dominantly Inherited Alzheimer Network. "White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease." PLoS ONE, vol. 13, no. 5, 2018, pp. e0195838. |
| Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. "Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease." J. Geophys. Res., vol. 546, no. 7659, 2017, pp. 564. |
| Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Dietzsch J, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Graff-Radford NR, Levin J, Galasko D, Quaid KA, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C. "Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease." Scientific reports, vol. 7, no. 1, 2017, pp. 1225. |
| Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, Salloway S, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD Sr, Mintun MA. "Effectiveness of Florbetapir PET Imaging in Changing Patient Management." Dementia and Geriatric Cognitive Disorders, vol. 44, no. 3-4, 2017, pp. 129-143. |
| Rasmussen SA, Noren G, Greenberg BD, Marsland R, McLaughlin NC, Malloy PJ, Salloway SP, Strong DR, Eisen JL, Jenike MA, Rauch SL, Baer L, Lindquist C. "Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive Disorder." Biological Psychiatry, vol. 84, no. 5, 2017, pp. 355-364. |
| Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, Xiong C, Fagan AM, Benzinger T, Buckles V, Erickson KI, Clarnette R, Shah T, Masters CL, Weiner M, Cairns N, Rossor M, Graff-Radford NR, Salloway S, Vöglein J, Laske C, Noble J, Schofield PR, Bateman RJ, Morris JC, Martins RN, Dominantly Inherited Alzheimer Network. "Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease." Alzheimer's & Dementia, vol. 13, no. 11, 2017, pp. 1197-1206. |
| Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C. "Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease." Alzheimer's & dementia (Amsterdam, Netherlands), vol. 9, 2017, pp. 25-34. |
| Alber J, Lee AKW, Menard W, Monast D, Salloway SP. "Recruitment of At-Risk Participants for Clinical Trials: A Major Paradigm Shift for Alzheimer's Disease Prevention." The journal of prevention of Alzheimer's disease, vol. 4, no. 4, 2017, pp. 213-214. |
| Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators. "Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition." Brain, vol. 140, no. 3, 2017, pp. 748-763. |
| Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C, DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. "The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model." Alzheimer's & Dementia, vol. 13, no. 1, 2017, pp. 8-19. |
| Lozano AM, Fosdick L, Chakravarty MM, Leoutsakos JM, Munro C, Oh E, Drake KE, Lyman CH, Rosenberg PB, Anderson WS, Tang-Wai DF, Pendergrass JC, Salloway S, Asaad WF, Ponce FA, Burke A, Sabbagh M, Wolk DA, Baltuch G, Okun MS, Foote KD, McAndrews MP, Giacobbe P, Targum SD, Lyketsos CG, Smith GS. "A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease." Journal of Alzheimer's disease : JAD, vol. 54, no. 2, 2016, pp. 777-87. |
| Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. "Alzheimer's disease." The Lancet, vol. 388, no. 10043, 2016, pp. 505-17. |
| Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network. "BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease." Brain, vol. 139, no. Pt 10, 2016, pp. 2766-2777. |
| Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL, Dominantly Inherited Alzheimer Network. "Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group." PLoS ONE, vol. 11, no. 9, 2016, pp. e0163669. |
| Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network (DIAN). "Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)." The Lancet Neurology, vol. 15, no. 13, 2016, pp. 1317-1325. |
| Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr, Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria." Alzheimer's & Dementia, vol. 12, no. 3, 2016, pp. 292-323. |
| Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL, Dominantly Inherited Alzheimer Network. "Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group." PLoS ONE, vol. 11, no. 3, 2016, pp. e0152082. |
| Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, Egan JC, Feldman H, Lappin D, Truyen L, Salloway S, Sperling R, Vradenburg G. "Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network." The journal of prevention of Alzheimer's disease, vol. 3, no. 2, 2016, pp. 114-120. |
| Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, Langbaum JB, Schneider L, Hendrix S, Wilcock G, Molinuevo JL, Ritchie C, Ousset PJ, Cummings J, Sperling R, DeKosky ST, Lovestone S, Hampel H, Petersen R, Legrand V, Egan M, Randolph C, Salloway S, Weiner M, Vellas B. "Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force." The journal of prevention of Alzheimer's disease, vol. 3, no. 2, 2016, pp. 68-74. |
| Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease." Nature, vol. 537, no. 7618, 2016, pp. 50-6. |
| Rossetti MA, Piryatinsky I, Ahmed FS, Klinge PM, Relkin NR, Salloway S, Ravdin LD, Brenner E, Malloy PF, Levin BE, Broggi M, Gavett R, Maniscalco JS, Katzen H. "Two Novel Psychomotor Tasks in Idiopathic Normal Pressure Hydrocephalus." Journal of the International Neuropsychological Society, vol. 22, no. 3, 2016, pp. 341-9. |
| Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Ryan NS, Förster S, Laske C, Schofield PR, Sperling RA, Salloway S, Correia S, Jack C Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM, Dominantly Inherited Alzheimer Network. "White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network." Annals of neurology, vol. 79, no. 6, 2016, pp. 929-39. |
| Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR, Bapineuzumab 301 and 302 Clinical Trial Investigators. "Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials." Neurology, vol. 85, no. 8, 2015, pp. 692-700. |
| Beriault, D. R., Diamandis, E. P., Portelius, E., Perret-Liaudet, A., Salloway, S. "Biomarkers, Assays, and Therapies for Alzheimer Disease." Clinical Chemistry, vol. 61, no. 7, 2015, pp. 903-908. |
| Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, Salloway S, Trojanowski JQ, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, Carrillo MC, Stephenson D, Snyder H, Liu E, Ware T, McKew J, Fields FO, Bain LJ, Bens C. "Building a roadmap for developing combination therapies for Alzheimer's disease." Expert Review of Neurotherapeutics, vol. 15, no. 3, 2015, pp. 327-33. |
| Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Förster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ, Dominantly Inherited Alzheimer Network. "Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease." Neurology, vol. 85, no. 9, 2015, pp. 790-8. |
| Stephenson D, Perry D, Bens C, Bain LJ, Berry D, Krams M, Sperling R, Dilts D, Luthman J, Hanna D, McKew J, Temple R, Fields FO, Salloway S, Katz R. "Charting a path toward combination therapy for Alzheimer's disease." Expert Review of Neurotherapeutics, vol. 15, no. 1, 2015, pp. 107-13. |
| 106. Holroyd K, Fosdick L, Smith G, Leoutsakos J, Munro C, Oh E, Drake K, Rosenberg P, Anderson W, Salloway S, Pendergrass C, Burke A, Wolk D, Tang-Wai D, Ponce F, Asaad W, Sabbagh M, Okun M, Baltuch G, Foote K, Targum S, Lozano A, Lyketsos C. "Deep brain stimulation targeting the fornix for mild Alzheimer Dementia: design of the ADvance randomized controlled trial." Open Access Journal of Clinical Trials, vol. 7, 2015, pp. 63-76. |
| Lim YY, Maruff P, Schindler R, Ott BR, Salloway S, Yoo DC, Noto RB, Santos CY, Snyder PJ. "Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease." Neurobiology of Aging, vol. 36, no. 10, 2015, pp. 2709-2715. |
| Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, Salloway S, Schofield PR, Cummings JL, Buckles V, Bateman R, Morris JC, Dominantly Inherited Alzheimer Network. "Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network." Brain, vol. 138, no. Pt 4, 2015, pp. 1036-45. |
| Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, Salloway S, Doody R, Aisen P, Task Force Members. "Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force." The journal of prevention of Alzheimer's disease, vol. 2, no. 2, 2015, pp. 128-135. |
| Monserrate AE, Ryman DC, Ma S, Xiong C, Noble JM, Ringman JM, Morris JC, Danek A, Müller-Sarnowski F, Clifford DB, McDade EM, Brooks WS, Darby DG, Masters CL, Weston PS, Farlow MR, Graff-Radford NR, Salloway SP, Fagan AM, Oliver A, Bateman RJ, Dominantly Inherited Alzheimer Network. "Factors associated with the onset and persistence of post-lumbar puncture headache." JAMA neurology, vol. 72, no. 3, 2015, pp. 325-32. |
| Correia S, Ahern DC, Rabinowitz AR, Farrer TJ, Smith Watts AK, Salloway S, Malloy PF, Deoni SC. "Lowering the Floor on Trail Making Test Part B: Psychometric Evidence for a New Scoring Metric." Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, vol. 30, no. 7, 2015, pp. 643-56. |
| Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S. "Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density." JAMA neurology, vol. 72, no. 3, 2015, pp. 287-94. |
| Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. "Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial." JAMA neurology, vol. 72, no. 11, 2015, pp. 1324-33. |
| Salloway, Stephen, Sperling, Reisa. "Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia." JAMA Neurology, vol. 72, no. 10, 2015, pp. 1106. |
| Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. "Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria." The Lancet Neurology, vol. 13, no. 6, 2014, pp. 614-29. |
| Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, Raichle M, Holtzman DM, Sperling RA, Mayeux R, Ghetti B, Ringman JM, Salloway S, McDade E, Rossor MN, Ourselin S, Schofield PR, Masters CL, Martins RN, Weiner MW, Thompson PM, Fox NC, Koeppe RA, Jack CR Jr, Mathis CA, Oliver A, Blazey TM, Moulder K, Buckles V, Hornbeck R, Chhatwal J, Schultz AP, Goate AM, Fagan AM, Cairns NJ, Marcus DS, Morris JC, Ances BM. "Functional connectivity in autosomal dominant and late-onset Alzheimer disease." JAMA neurology, vol. 71, no. 9, 2014, pp. 1111-22. |
| Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM, Dominantly Inherited Alzheimer Network. "Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease." Science Translational Medicine, vol. 6, no. 226, 2014, pp. 226ra30. |
| Snyder PJ, Lim YY, Schindler R, Ott BR, Salloway S, Daiello L, Getter C, Gordon CM, Maruff P. "Microdosing of scopolamine as a "cognitive stress test": rationale and test of a very low dose in an at-risk cohort of older adults." Alzheimer's & Dementia, vol. 10, no. 2, 2014, pp. 262-7. |
| Salloway S, Sperling R, Brashear HR. "Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease." New England Journal of Medicine, vol. 370, no. 15, 2014, pp. 1460. |
| Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network. "Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis." Neurology, vol. 83, no. 3, 2014, pp. 253-60. |
| Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab 301 and 302 Clinical Trial Investigators. "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease." New England Journal of Medicine, vol. 370, no. 4, 2014, pp. 322-33. |
| Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. "Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development." Alzheimer's & Dementia, vol. 9, no. 2, 2013, pp. 176-88. |
| Chhatwal JP, Schultz AP, Johnson K, Benzinger TL, Jack C Jr, Ances BM, Sullivan CA, Salloway SP, Ringman JM, Koeppe RA, Marcus DS, Thompson P, Saykin AJ, Correia S, Schofield PR, Rowe CC, Fox NC, Brickman AM, Mayeux R, McDade E, Bateman R, Fagan AM, Goate AM, Xiong C, Buckles VD, Morris JC, Sperling RA. "Impaired default network functional connectivity in autosomal dominant Alzheimer disease." Neurology, vol. 81, no. 8, 2013, pp. 736-44. |
| Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M. "MR imaging features of amyloid-related imaging abnormalities." AJNR. American journal of neuroradiology, vol. 34, no. 10, 2013, pp. 1958-65. |
| Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA, 45-A17 Study Group. "Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline." Alzheimer Disease & Associated Disorders, vol. 27, no. 1, 2013, pp. 4-15. |
| Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. "Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial." Revue neurologique, vol. 169, no. 10, 2013, pp. 737-43. |
| Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. "Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease." Proceedings of the National Academy of Sciences, vol. 110, no. 47, 2013, pp. E4502-9. |
| Wendell LC, Potter NS, Roth JL, Salloway SP, Thompson BB. "Successful management of severe neuroinvasive eastern equine encephalitis." Neurocritical Care, vol. 19, no. 1, 2013, pp. 111-5. |
| Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. "The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)." Alzheimer's & Dementia, vol. 9, no. 2, 2013, pp. 189-98. |
| Cash DM, Ridgway GR, Liang Y, Ryan NS, Kinnunen KM, Yeatman T, Malone IB, Benzinger TL, Jack CR Jr, Thompson PM, Ghetti BF, Saykin AJ, Masters CL, Ringman JM, Salloway SP, Schofield PR, Sperling RA, Cairns NJ, Marcus DS, Xiong C, Bateman RJ, Morris JC, Rossor MN, Ourselin S, Fox NC, Dominantly Inherited Alzheimer Network (DIAN). "The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study." Neurology, vol. 81, no. 16, 2013, pp. 1425-33. |
| Frakey LL, Salloway S, Buelow M, Malloy P. "A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease." J. Clin. Psychiatry, vol. 73, no. 6, 2012, pp. 796-801. |
| Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis." The Lancet Neurology, vol. 11, no. 3, 2012, pp. 241-9. |
| Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM, Alzheimer's Disease Neuroimaging Initiative., Pediatric Imaging, Neurocognition, and Genetics Study., Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H. "Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans." Proceedings of the National Academy of Sciences, vol. 109, no. 10, 2012, pp. 3985-90. |
| Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Dominantly Inherited Alzheimer Network. "Clinical and biomarker changes in dominantly inherited Alzheimer's disease." New England Journal of Medicine, vol. 367, no. 9, 2012, pp. 795-804. |
| Salloway S. "Clinical and pathological examples of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia." Medicine and health, Rhode Island, vol. 95, no. 7, 2012, pp. 207-9. |
| Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. "Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network." Clinical investigation, vol. 2, no. 10, 2012, pp. 975-984. |
| Epstein-Lubow G, Gaudiano B, Darling E, Hinckley M, Tremont G, Kohn R, Marino LJ Jr, Salloway S, Grinnell R, Miller IW. "Differences in depression severity in family caregivers of hospitalized individuals with dementia and family caregivers of outpatients with dementia." The American Journal of Geriatric Psychiatry, vol. 20, no. 9, 2012, pp. 815-9. |
| Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, AAB-001 201/202 Investigators. "Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease." Archives of Neurology, vol. 69, no. 8, 2012, pp. 1002-10. |
| Carmichael OT, Salloway S. "Imaging markers of incipient dementia: the white matter matters." Neurology, vol. 79, no. 8, 2012, pp. 726-7. |
| Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. "Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease." Archives of Neurology, vol. 69, no. 11, 2012, pp. 1430-40. |
| Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J. "Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease." American journal of Alzheimer's disease and other dementias, vol. 27, no. 6, 2012, pp. 421-32. |
| Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM, ELND005-AD201 Investigators. "A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease." Neurology, vol. 77, no. 13, 2011, pp. 1253-62. |
| Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. "Amyloid-β associated cortical thinning in clinically normal elderly." Annals of neurology, vol. 69, no. 6, 2011, pp. 1032-42. |
| Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. "Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease." Alzheimer's research & therapy, vol. 3, no. 1, 2011, pp. 1. |
| Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li C, Goldman R. "Identifying amnestic mild cognitive impairment in primary care: a feasibility study." Clinical Drug Investigation, vol. 31, no. 7, 2011, pp. 483-91. |
| Salloway S. "New lessons from the Alzheimer's Disease Neuroimaging Initiative." Archives of Neurology, vol. 68, no. 1, 2011, pp. 19-21. |
| Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. "Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study." Clinical Therapeutics, vol. 32, no. 7, 2010, pp. 1234-51. |
| Epstein-Lubow G, Gaudiano BA, Hinckley M, Salloway S, Miller IW. "Evidence for the validity of the American Medical Association's caregiver self-assessment questionnaire as a screening measure for depression." Journal of the American Geriatrics Society, vol. 58, no. 2, 2010, pp. 387-8. |
| Brennan-Krohn T, Salloway S, Correia S, Dong M, de la Monte SM. "Glial vascular degeneration in CADASIL." Journal of Alzheimer's disease : JAD, vol. 21, no. 4, 2010, pp. 1393-402. |
| Román GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, Moline M, Kumar D, Schindler R, Posner H. "Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size." Stroke, vol. 41, no. 6, 2010, pp. 1213-21. |
| Doody RS, Ferris S, Salloway S, Yijun Sun, Goldman R, Yikang Xu, Gao J, Murthy AK. "Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study." American journal of Alzheimer's disease and other dementias, vol. 25, no. 2, 2010, pp. 155-9. |
| Wilkinson D, Róman G, Salloway S, Hecker J, Boundy K, Kumar D, Posner H, Schindler R. "The long-term efficacy and tolerability of donepezil in patients with vascular dementia." International Journal of Geriatric Psychiatry, vol. 25, no. 3, 2010, pp. 305-13. |
| Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators. "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease." Neurology, vol. 73, no. 24, 2009, pp. 2061-70. |
| Salloway S, Correia S. "Alzheimer disease: time to improve its diagnosis and treatment." Cleveland Clinic Journal of Medicine, vol. 76, no. 1, 2009, pp. 49-58. |
| Salloway S. "Current and future treatments for Alzheimer's disease." CNS Spectrums, vol. 14, no. 8 Suppl 7, 2009, pp. 4-7; discussion 16-8. |
| Malone, Donald A., Dougherty, Darin D., Rezai, Ali R., Carpenter, Linda L., Friehs, Gerhard M., Eskandar, Emad N., Rauch, Scott L., Rasmussen, Steven A., Machado, Andre G., Kubu, Cynthia S., Tyrka, Audrey R., Price, Lawrence H., Stypulkowski, Paul H., Giftakis, Jonathon E., Rise, Mark T., Malloy, Paul F., Salloway, Stephen P., Greenberg, Benjamin D. "Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression." Biological Psychiatry, vol. 65, no. 4, 2009, pp. 267-275. |
| Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK. "Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial." Neurology, vol. 72, no. 18, 2009, pp. 1555-61. |
| Stopa EG, Butala P, Salloway S, Johanson CE, Gonzalez L, Tavares R, Hovanesian V, Hulette CM, Vitek MP, Cohen RA. "Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype." Stroke, vol. 39, no. 3, 2008, pp. 814-21. |
| Greenberg, B D, Gabriels, L A, Malone, D A, Rezai, A R, Friehs, G M, Okun, M S, Shapira, N A, Foote, K D, Cosyns, P R, Kubu, C S, Malloy, P F, Salloway, S P, Giftakis, J E, Rise, M T, Machado, A G, Baker, K B, Stypulkowski, P H, Goodman, W K, Rasmussen, S A, Nuttin, B J. "Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience." Molecular Psychiatry, vol. 15, no. 1, 2008, pp. 64-79. |
| Salloway S, Mintzer J, Weiner MF, Cummings JL. "Disease-modifying therapies in Alzheimer's disease." Alzheimer's & Dementia, vol. 4, no. 2, 2008, pp. 65-79. |
| Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS. "Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL." The Lancet Neurology, vol. 7, no. 4, 2008, pp. 310-8. |
| Salloway S, Correia S, Richardson S. "Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI." International Psychogeriatrics, vol. 20, no. 1, 2008, pp. 40-6. |
| Correia S, Lee SY, Voorn T, Tate DF, Paul RH, Zhang S, Salloway SP, Malloy PF, Laidlaw DH. "Quantitative tractography metrics of white matter integrity in diffusion-tensor MRI." NeuroImage, vol. 42, no. 2, 2008, pp. 568-581. |
| Salloway S. "Taking the next steps in the treatment of Alzheimer's disease: disease-modifying agents." CNS Spectrums, vol. 13, no. 3 Suppl 3, 2008, pp. 11-4. |
| Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group. "Galantamine treatment of vascular dementia: a randomized trial." Neurology, vol. 69, no. 5, 2007, pp. 448-58. |
| Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. "Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria." The Lancet Neurology, vol. 6, no. 8, 2007, pp. 734-46. |
| Grundman M, Petersen RC, Bennett DA, Feldman HH, Salloway S, Visser PJ, Thal LJ, Schenk D, Khachaturian Z, Thies W, Alzheimer's Association Research Roundtable. "Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?." Alzheimer's & Dementia, vol. 2, no. 3, 2006, pp. 220-33. |
| Salloway S. "Improving the diagnosis and treatment of Alzheimer's disease." Medicine and health, Rhode Island, vol. 89, no. 5, 2006, pp. 166-8. |
| Steffens DC, Otey E, Alexopoulos GS, Butters MA, Cuthbert B, Ganguli M, Geda YE, Hendrie HC, Krishnan RR, Kumar A, Lopez OL, Lyketsos CG, Mast BT, Morris JC, Norton MC, Peavy GM, Petersen RC, Reynolds CF, Salloway S, Welsh-Bohmer KA, Yesavage J. "Perspectives on depression, mild cognitive impairment, and cognitive decline." Archives of General Psychiatry , vol. 63, no. 2, 2006, pp. 130-8. |
| Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR, Leifer B, Mills C, Minkoff N, Orland B, Reichman WE, Salloway S. "Recommendations for best practices in the treatment of Alzheimer's disease in managed care." The American journal of geriatric pharmacotherapy, vol. 4 Suppl A, 2006, pp. S9-S24; quiz S25-S28. |
| Greenberg, Benjamin D, Malone, Donald A, Friehs, Gerhard M, Rezai, Ali R, Kubu, Cynthia S, Malloy, Paul F, Salloway, Stephen P, Okun, Michael S, Goodman, Wayne K, Rasmussen, Steven A. "Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder." Neuropsychopharmacology, vol. 31, no. 11, 2006, pp. 2384-93. |
| BELANGER, H, WILDERWILLIS, K, MALLOY, P, SALLOWAY, S, HAMMAN, R, GRIGSBY, J. "Assessing motor and cognitive regulation in AD, MCI, and controls using the Behavioral Dyscontrol Scale." Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, vol. 20, no. 2, 2005, pp. 183-189. |
| Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. "Donepezil in vascular dementia: combined analysis of two large-scale clinical trials." Dementia and Geriatric Cognitive Disorders, vol. 20, no. 6, 2005, pp. 338-44. |
| Maclean AV, Woods R, Alderson LM, Salloway SP, Correia S, Cortez S, Stopa EG. "Spontaneous lobar haemorrhage in CADASIL." Journal of Neurology, Neurosurgery & Psychiatry, vol. 76, no. 3, 2005, pp. 456-7. |
| Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S, Donepezil 401 Study Group. "Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial." Neurology, vol. 63, no. 4, 2004, pp. 651-7. |
| Malloy P, Belanger H, Hall S, Aloia M, Salloway S. "Assessing visuoconstructional performance in AD, MCI and normal elderly using the Beery Visual-Motor Integration Test." The Clinical Neuropsychologist, vol. 17, no. 4, 2003, pp. 544-550. |
| Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R, Donepezil 307 Vascular Dementia Study Group. "Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial." Stroke, vol. 34, no. 10, 2003, pp. 2323-30. |
| Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. "Executive dysfunction and apathy predict functional impairment in Alzheimer disease." The American Journal of Geriatric Psychiatry, vol. 11, no. 2, 2003, pp. 214-21. |
| Salloway S, Correia S, Peck J, Harrington C. "Dementia with Lewy bodies: a diagnostic and treatment challenge." Medicine and health, Rhode Island, vol. 85, no. 7, 2002, pp. 207-9. |
| Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E. "Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease." Journal of the Neurological Sciences, vol. 203-204, 2002, pp. 183-7. |
| Rymer S, Salloway S, Norton L, Malloy P, Correia S, Monast D. "Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease." Alzheimer Disease & Associated Disorders, vol. 16, no. 4, 2002, pp. 248-53. |
| Salloway S, Correia S, Boyle P, Malloy P, Schneider L, Lavretsky H, Sackheim H, Roose S, Krishnan KR. "MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression." Journal of the Neurological Sciences, vol. 203-204, 2002, pp. 227-33. |
| Salloway S, Boyle PA, Correia S, Malloy PF, Cahn-Weiner DA, Schneider L, Krishnan KR, Nakra R. "The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients." The American Journal of Geriatric Psychiatry, vol. 10, no. 1, 2002, pp. 107-11. |
| Norton LE, Malloy PF, Salloway S. "The impact of behavioral symptoms on activities of daily living in patients with dementia." The American Journal of Geriatric Psychiatry, vol. 9, no. 1, 2001, pp. 41-8. |
| Cahn-Weiner DA, Malloy PF, Boyle PA, Marran M, Salloway S. "Prediction of functional status from neuropsychological tests in community-dwelling elderly individuals." The Clinical Neuropsychologist, vol. 14, no. 2, 2000, pp. 187-95. |
| LaFrance WC Jr, Lauterbach EC, Coffey CE, Salloway SP, Kaufer DI, Reeve A, Royall DR, Aylward E, Rummans TA, Lovell MR. "The use of herbal alternative medicines in neuropsychiatry. A report of the ANPA Committee on Research." The Journal of neuropsychiatry and clinical neurosciences, vol. 12, no. 2, 2000, pp. 177-92. |
| Cohen RA, Kaplan RF, Zuffante P, Moser DJ, Jenkins MA, Salloway S, Wilkinson H. "Alteration of intention and self-initiated action associated with bilateral anterior cingulotomy." The Journal of neuropsychiatry and clinical neurosciences, vol. 11, no. 4, 1999, pp. 444-53. |
| Rummans TA, Lauterbach EC, Coffey CE, Royall DR, Cummings JL, Salloway S, Duffy J, Kaufer D. "Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research." The Journal of neuropsychiatry and clinical neurosciences, vol. 11, no. 2, 1999, pp. 176-89. |
| Salloway S, Hong J. "CADASIL syndrome: a genetic form of vascular dementia." Journal of Geriatric Psychiatry and Neurology, vol. 11, no. 2, 1998, pp. 71-7. |
| Jenkins M, Malloy P, Salloway S, Cohen R, Rogg J, Tung G, Kohn R, Westlake R, Johnson EG, Richardson E. "Memory processes in depressed geriatric patients with and without subcortical hyperintensities on MRI." Journal of Neuroimaging, vol. 8, no. 1, 1998, pp. 20-6. |
| Lauterbach EC, Cummings JL, Duffy J, Coffey CE, Kaufer D, Lovell M, Malloy P, Reeve A, Royall DR, Rummans TA, Salloway SP. "Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association." The Journal of neuropsychiatry and clinical neurosciences, vol. 10, no. 3, 1998, pp. 249-66. |
| Cummings JL, Coffey CE, Duffy JD, Lauterbach EC, Lovell M, Malloy PF, Royall DR, Rummans TA, Salloway S. "The clinician-scientist in neuropsychiatry: a position statement from the Committee on Research of the American Neuropsychiatric Association." The Journal of neuropsychiatry and clinical neurosciences, vol. 10, no. 1, 1998, pp. 1-9. |
| Malloy PF, Cummings JL, Coffey CE, Duffy J, Fink M, Lauterbach EC, Lovell M, Royall D, Salloway S. "Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association." The Journal of neuropsychiatry and clinical neurosciences, vol. 9, no. 2, 1997, pp. 189-97. |
| Jenkins MA, Cimino C, Malloy PF, Salloway S, Cohen R, Kohn R, Westlake R. "Neuropsychiatric factors in the illusion of visitors among geriatric patients: a case series." Journal of Geriatric Psychiatry and Neurology, vol. 10, no. 2, 1997, pp. 79-87. |
| Salloway S, White J. "Paroxysmal limbic disorders in neuropsychiatry." The Journal of neuropsychiatry and clinical neurosciences, vol. 9, no. 3, 1997, pp. 403-19. |
| Harrington C, Salloway S. "The diagnosis and treatment of post-stroke depression." Medicine and health, Rhode Island, vol. 80, no. 6, 1997, pp. 181-7. |
| Mega MS, Cummings JL, Salloway S, Malloy P. "The limbic system: an anatomic, phylogenetic, and clinical perspective." The Journal of neuropsychiatry and clinical neurosciences, vol. 9, no. 3, 1997, pp. 315-30. |
| Salloway S, Stewart CF, Israeli L, Morales X, Rasmussen S, Blitzer A, Brin MF. "Botulinum toxin for refractory vocal tics." Mov. Disord., vol. 11, no. 6, 1996, pp. 746-8. |
| Salloway S. "Clinical-pathological case conference: depression, behavior change, and subcortical dementia in a 57-year-old woman." The Journal of neuropsychiatry and clinical neurosciences, vol. 8, no. 2, 1996, pp. 215-21. |
| Salloway S, Mermel LA, Seamans M, Aspinall GO, Nam Shin JE, Kurjanczyk LA, Penner JL. "Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3." Infection and Immunity, vol. 64, no. 8, 1996, pp. 2945-9. |
| Salloway S, Malloy P, Kohn R, Gillard E, Duffy J, Rogg J, Tung G, Richardson E, Thomas C, Westlake R. "MRI and neuropsychological differences in early- and late-life-onset geriatric depression." Neurology, vol. 46, no. 6, 1996, pp. 1567-74. |
| Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED, Westlake R. "Subcortical hyperintensities on MRI and activities of daily living in geriatric depression." The Journal of neuropsychiatry and clinical neurosciences, vol. 8, no. 4, 1996, pp. 404-11. |
| Coffey CE, Cummings JL, Duffy JD, Fink M, Lauterbach EC, Lovell MR, Malloy P, Nussbaum PD, Royall DR, Salloway S. "Assessment of treatment outcomes in neuropsychiatry: a report from the Committee on Research of the American Neuropsychiatric Association." The Journal of neuropsychiatry and clinical neurosciences, vol. 7, no. 3, 1995, pp. 287-9. |
| Salloway SP. "Diagnosis and treatment of patients with "frontal lobe" syndromes." The Journal of neuropsychiatry and clinical neurosciences, vol. 6, no. 4, 1994, pp. 388-98. |
| Salloway S, Cummings J. "Subcortical disease and neuropsychiatric illness." The Journal of neuropsychiatry and clinical neurosciences, vol. 6, no. 2, 1994, pp. 93-9. |
| Campbell JJ 3rd, Duffy JD, Salloway SP. "Treatment strategies for patients with dysexecutive syndromes." The Journal of neuropsychiatry and clinical neurosciences, vol. 6, no. 4, 1994, pp. 411-8. |
| Tate C, Salloway S, Rogg J. "Case conference: behavior change, hallucinations, and memory loss in a 25-year-old man." The Journal of neuropsychiatry and clinical neurosciences, vol. 5, no. 4, 1993, pp. 435-41. |
| Salloway S, Duffy J. "Neuropsychiatric aspects of depression." Rhode Island medicine, vol. 76, no. 8, 1993, pp. 425-30. |
| Salloway S. "Neuropsychiatric aspects of movement disorders." Rhode Island medicine, vol. 76, no. 11, 1993, pp. 549-52. |
| Karper LP, Salloway SP, Seibyl JP, Krystal JH. "Prolonged postictal encephalopathy in two patients with clozapine-induced seizures." The Journal of neuropsychiatry and clinical neurosciences, vol. 4, no. 4, 1992, pp. 454-7. |
| Fogel BS, Duffy J, McNamara ME, Salloway S. "Skeptics and enthusiasts in neuropsychiatry." The Journal of neuropsychiatry and clinical neurosciences, vol. 4, no. 4, 1992, pp. 458-62. |
| Farran CJ, Keane-Hagerty E, Salloway S, Kupferer S, Wilken CS. "Finding meaning: an alternative paradigm for Alzheimer's disease family caregivers." The Gerontologist, vol. 31, no. 4, 1991, pp. 483-9. |
| Salloway S, Price LH, Charney DS, Shapiro M. "Multiple sclerosis presenting as major depression: a diagnosis suggested by MRI scan but not CT scan." J. Clin. Psychiatry, vol. 49, no. 9, 1988, pp. 364-6. |
I am the founding director of the Butler Hospital Memory and Aging Program, a talented multidisciplinary research team, dedicated to developing biomarkers and new medications to prevent or modify the progression of Alzheimer’s disease (AD). The program has become an internationally recognized center for AD clinical research. We utilize cutting edge fluid and imaging biomarkers and novel cognitive assessments, in collaboration with other AD research centers, to map the evolution of AD pathophysiology and determine AD risk and disease stage in both autosomal dominant and sporadic AD. This approach has provided convincing evidence that the core pathological components of AD neuropathology begin accumulating 10-20 years before cognitive decline, which has helped open the era of Alzheimer’s prevention. This work has also led to FDA approval of three amyloid PET tracers and we anticipate FDA approval of the first tau PET tracer soon. We are also testing targeted treatments such as BACE inhibitors and monoclonal antibodies, alone and in combination, to lower amyloid plaques and neurofibrillary tangles and novel approaches, such as deep brain stimulation to alter the course of AD. Given the magnitude of the problem, we are developing strategies for broad community engagement to recruit a large cohort of cognitively normal individuals at increased risk for AD to participate in prevention trials. This involves recruiting thousands of participants willing to find out about their risk for AD and building an army of volunteers to fight Alzheimer’s disease. Our team, led by Jessica Alber, PhD, and Athene Lee, PhD, is studying the psychological impact of disclosure of AD risk.
In 2018 we will be launching a landmark study to map retinal changes in preclinical Alzheimer’s disease in collaboration with Peter Snyder, PhD, from the University of Rhode Island. Retinal imaging will be conducted with the highly innovative Heidelberg SPECTRALIS II® OCT Plus with BluePeak™ and Nsite Analytics™, for measuring the structure of the human retina. The device is a combination of a confocal scanning laser ophthalmoscope (cSLO) and a spectral-domain optical coherence tomography (OCT). The combination of these techniques allows for high 3-D resolution imaging of the retina and optic nerve and easy detection, localization, and quantification of retinal amyloid deposits. This equipment is capable of examining structural, metabolic, and vascular retinal changes, elevating its utility in both clinical and research arenas. Brain amyloid PET scans will be performed in a subset of patients to assess retinal amyloid as a predictor of brain amyloid. We will also be correlating plasma biomarkers with amyloid PET and using real-time digital assessments to help predict amyloid status and cognitive decline. Validating retinal imaging and innovative plasma and digital measures as a predictor of brain amyloid would be a widely-available economical approach to speed the development of preventative therapies.
Cerebrovascular disease plays an important role in the pathophysiology and expression of dementia and our program has a long-standing interest in studying cerebrovascular contributions to cognitive impairment. We are a lead center for the study of CADASIL, an autosomal dominant form of brain small artery disease causing stroke and dementia. In 2018 we will be collaborating with Paula Grammas at URI and other Rhode Island memory programs in an innovative treatment trial of a thrombin inhibitor for patients with early AD.
Alzheimer’s disease is a major public health problem that burdens patients and families and threatens to destabilize our healthcare economy. Congress has developed a National Plan to fight Alzheimer’s disease with a goal of developing treatments to prevent or effectively treat AD by 2025. The Brown University Institutes for Brain Science (BIBS) and Translational Science (BITS) have made a major commitment to AD translational research and our team is excited to be working closely with other Brown investigators to firmly establish the Alpert Medical School as a global leader in Alzheimer’s research.
Funded Research (active)
Alzheimer’s Clinical Trials Consortium (ACTC)
U24AG057437 Paul Aisen, Reisa Sperling, Ronald Petersen, PIs
National Institute of Aging
$769,511
03/2018-02/2023
Site PI
Longitudinal Early-onset Alzheimer’s Disease Study (LEADS)
1R56AG057195 Liana Apostolova, PI
National Institute of Aging/Alzheimer’s Association/University of Indiana
10/2018-09/2023
Site PI
Dominantly inherited Alzheimer’s Network
5U19AG032438-01 John Morris, PI
NIA/Washington University
$324,000
2009-2019
Site PI
A principal open-labeled study to compare the brain uptake of 18F]flutemetamol with brain fibrillar Aβ levels determined post-mortem.
GE 067-007
2011-present
Site PI
$140,000
Dominantly Inherited Alzheimer’s Network: Opportunity to Prevent Dementia.
Alzheimer’s Association, NIA U01AG042791
2012-present
Project Leader, Gantenerumab
$42,885
A randomized, double-blinded, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer’s disease
Biogen
2012-present
Site PI
$300,000
A 12-month, masked, randomized, controlled, feasibility study to evaluate the efficacy, safety, and tolerability of deep brain stimulation of the fornix in patients with mild probable Alzheimer’s disease
Functional Neuromodulation
2012-present
Site PI
$300,000
Amyloid pathology and shunt response in normal pressure hydrocephalus F-AV-45-A14
Avid Radiopharmaceuticals-investigator-initiated
2012-present
PI
$125,000
An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer’s disease
Avid Radiopharmaceuticals
2014-present
Investigator
$380,000
Anti-amyloid in asymptomatic Alzheimer’s disease
National Institute on Aging/Lilly
2014-present
PI
$480,000
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).
Merck
2014-present
$225,000
Global Alzheimer’s Network Award
GAP-NET
2015-present
Site PI
$200,000
A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of aducanumab (BIIB037) in subjects with early Alzheimer’s disease
Biogen
2015-present
Site PI
$990,000
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration: THE LEARN STUDY ADC-051
NIA-Alzheimer’s Treatment Research Institute
2015-present
Site PI
$120,000
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia
Lilly
2016-2020
Phase 3 trial of a beta secretase inhibitor for patients with mild Alzheimer’s dementia
Site PI
Alzheimer’s Disease Neuroimaging Initiative ADNI-3
NIA UO1AG024904
7/1/2011-6/30/2021
Site PI
$130,000
Imaging Dementia-Evidence for Amyloid Scanning Trial
Center for Medicare Services
2/1/16-2/1/19
Site PI
$70,000
A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease
Novartis/Banner/NIA
6/11/16-6/11/2022
$740,000
A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease
Novartis/Banner
7/1/17-7/1/23
Site PI
$960,000
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic at Risk for Developing Alzheimer’s Dementia
Janssen
4/1/17-4/1/23
Site PI
$600,000
Longitudinal evaluation of [18F]MNI-798 as a PET radioligand for imaging tau in the brain of patients with prodromal, mild and moderate Alzheimer’s disease compared to healthy volunteers
Genentech
8/1/16-2/1/18
Site PI
$48,000
A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy, and safety study of MTAU9937A in patients with prodromal to mild Alzheimer’s disease.
Genentech
12/6/17-12/6/21
Site PI
$440,00
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.
Eisai
10/28/17-10/28/21
Site PI
$310,000
Notable Completed Studies
Subcortical microvascular disease in geriatric depression
National Institute of Mental Health 1 K08 MH01487
$752,994
1999-2004
Principal Investigator
Genetic Models of Human Dementia
P20 RR15578-01 (a project of the Brown Center for Genetics and Genomics COBRE total grant $11,219,863)
$1,013,374
2000-2005
Co-Principal Investigator (Justin Fallon, subproject PI)
NIA ZAG1 FAS-5 J1 Institutional National Research Service Award
Dementia Research Fellowship T-32 (Paul Malloy, PI)
$1,492,665
2003-2008
Description: Dementia research fellowship for 2, 2-year post-docs in 2003 increasing to 4 2-year positions.
co-PI with Richard Besdine
An 18 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.
Eisai
2005-6
$160,000
A phase III, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild-moderate Alzheimer’s disease who are apolipoprotein E4 carriers and non-carriers
Elan Pharmaceuticals, Janssen Alzheimer’s Immunotherapy
2008-2012
$519,998
Chair, Investigator Steering Committee
| Year | Degree | Institution |
|---|---|---|
| 1985 | MD | Stanford University |
| 1981 | MS | University of California, Berkeley |
| 1975 | BA | Antioch College |
| Resident | Yale University School of Medicine, neurology and psychiatry | 1986-1991 |
1975-1977 Thomas J. Watson Fellow
1981-1985 Roland Jackson Scholar - fellowship support for medical training and research
1984 Rock Sleyster Award - National AMA Scholarship in Psychiatry
1985 Stanford University Primary Care Program Award for Outstanding Achievement in Clinical Teaching
1985 Stanford Medical School - Honors in Research
1987-1989 American Psychiatric Association Burroughs - Wellcome Fellow
1995 Fellow, Summer Geriatric Research Institute American Association of Geriatric Psychiatry, UC San Diego
1995-6 Surdna Foundation Fellow for Geriatric Research - Brown University
1995 Outstanding Teaching Award - Brown University Department of Psychiatry and Human Behavior
1996 Distinguished Visiting Professor Wilford Hall Medical Center, San Antonio, Texas
1998 Care New England Care Awards Honorable Mention, Butler Hospital Memory Disorders Program
1999 Brown University Honorary Master of Arts Eundem
2000 Fellow, American Neuropsychiatric Association
2001 Outstanding Teaching Award for Undergraduate Medical Student Education, Brown Medical School
2004 Fellow, American Academy of Neurology
2004 Dean’s Teaching Excellence Award, Brown Medical School
2006 Dean’s Teaching Excellence Award, Brown Medical School
2009 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2010 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2011 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2011 US News and World Report Top Doctors in the United States
2013 Castle Connolly Top Doctors
2013 Outstanding Teaching Award in the Geriatric Fellowship Training Program
2013 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2014 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2016 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2017 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2018 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
2019 Elected to Rhode Island Heritage Hall of Fame, May 2019
2019 Named 2019 Rhode Island Man of the Year by GoLocalProv
| Name | Title |
|---|---|
| Ott, Brian | Professor Emeritus of Neurology |
| Rasmussen, Steven | Professor of Psychiatry and Human Behavior |
ACADEMIC APPOINTMENTS
1983-1985 Lecturer in Primary Care Internal Medicine, Stanford Medical School
1990-1991 Instructor in Neurology, Yale University School of Medicine
1991-1998 Assistant Professor, Department of Clinical Neurosciences, Brown Medical School
1993-1998 Assistant Professor, Department of Psychiatry and Human Behavior Brown Medical School
1998-2004 Associate Professor; Department of Clinical Neurosciences, Brown Medical School
1998-2004 Associate Professor; Department Psychiatry and Human Behavior, Brown Medical School
2004-present Professor, Department of Clinical Neurosciences, Brown Medical School
2004-present Professor, Department Psychiatry and Human Behavior, Brown Medical School
2018-2023 Martin M. Zucker Professor of Psychiatry and Human Behavior, Brown Medical School
HOSPITAL APPOINTMENTS
1987-1991 Emergency Psychiatric Privileges, Hospital of St. Raphael, New Haven, CT
1990-1991 Staff Physician, West Haven VA Medical Center
1991-present Director of Neurology, Butler Hospital, Providence, RI
1991-present Neurology Staff, Rhode Island Hospital, Providence, RI
1992-present Co-director, Laboratory for Quantitative Neuroimaging, Butler Hospital
1997-2022 Director, Butler Hospital Memory and Aging Program
OTHER APPOINTMENTS
EDITORIAL BOARD
1994-present Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences
1997-2000 Editorial Advisory Board, GeroPsychiatry Report
2004-2007 Editorial Board Applied Neurology
2014-present Journal of Prevention of Alzheimer’s Disease
2014-present Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring
REVIEWER
Journals
Aging and Mental Health, 2006-present
Alzheimer’s Disease and Associated Disorders, 2004-present
Alzheimer’s and Dementia, 2007-present
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2016-present
American Journal of Geriatric Psychiatry, 2000-present
American Journal of Psychiatry, 2001-present
American Journal of Psychiatry and the Law, 2000-present
Annals of Internal Medicine, 2001-present
Annals of Neurology, 2012-present
Archives of Neurology, 2005-present
Biological Psychiatry, 2017-present
BMC Geriatrics, 2007-present
BMC Neurology, 2013-present
Canadian Journal of Neurological Sciences, 2006-present
CNS Spectrums, 2000-2008
Dementia and Geriatric Cognitive Disorders, 2005-present
European Journal of Neurology 2005-present
European Journal of Nuclear Medicine and Medical Imaging, 2013-present
Expert Opinion-2007-present
Frontiers Aging Neuroscience-2017-present
International Journal of Psychiatry in Clinical Practice, 2006-present
International Psychogeriatrics, 2006-present
Journal of Affective Disorders, 1997-present
Journal of the American Medical Association- 2014-present
Journal of Clinical Psychiatry, 1997-present
Journal of the American Geriatrics Society, 2007-present
Journal of Geriatric Psychiatry and Neurology, 1998-present
Journal of Neuroimaging 2016-present
Journal of Neurological Sciences, 2007-present
Journal of Neurology, 2006-present
Journal of Neuropsychiatry and Clinical Neurosciences, 1993-present
Lancet Neurology-2015-present
Medical Letter, 2006-present
Nature Communications-2017-present
Nature Reviews Neurology 2009-present
Neurobiology of Aging, 1998-present
Neuroepidemiology, 2001-present
Neurology, 2002-present
Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1993-present
Neuropsychopharmacology, 2001-present
Neuroscience Letters, 2010-present
New England Journal of Medicine, 2008-present
PLOS ONE, 2013-present
Proceedings of the national Academy of Sciences, 2017-present
Psychopharmacology 2003-present
Psychosomatics, 1999-present
Science Translational Medicine-2017-present
Southern Medical Journal, 1998-2002
Stroke, 2001-present
Tohoku Journal of Experimental Medicine, 2006-present
National Institutes of Health
National Strategy for Clinical Studies Recruitment and Participation: Capacity Building, 2017-present
Clinical Development in Frontotemporal Disorders, National Institute of Neurological Disorders and Stroke/The Association for Frontotemporal Degeneration, Washington, D.C, June, 2012
National Institute on Aging Alzheimer’s Disease Clinical Centers Study Section-ad hoc reviewer 2010-present
National Institute on Aging Neuroscience Branch Ad-hoc grant reviewer, 2001-present
NIMH Advisory Panel “Perspectives on Depression, Mild Cognitive Impairment, and Cognitive Decline,” 2003-present
NINDS Genetics of Vascular Cognitive Impairment Study Group, 2004-present
NINDS Special Emphasis Panel ZNS1 SNRB-S, 2004
Adult Psychopathology and Disorders of Aging IRG, February, 2005-present
NINDS Vascular Cognitive Impairment Harmonization Criteria Workshop, April, 2005
Professional Societies, Universities and Research Foundations
Alzheimer’s Association and Related Disorders Inc., 1994-present
Alzheimer’s Association International Conference, 2016-present
Alzheimer’s Foundation of America Medical Advisory Board, 2003-present
American Academy of Neurology, 1994-present
American Neuropsychiatric Association, 1991-present
American Psychiatric Association, 1993-present
Dana Foundation-2014-present
Harvard University Center for Neurodegeneration and Repair External Peer Review Committee, 1999-2004
German Research Foundation-2016-present
Hydrocephalus 2012, 2012-present
Institute for the Study of Aging Scientific Review Board, 2003-present
International Stroke Conference 2009-present
Lewy Body Dementia Association 2017-present
Medical Research Council (England), 2009-present
Ontario Mental Health Foundation, 2011-present
The Michael J Fox Foundation for Parkinson’s Disease Research, 2008-present
The New York Academy of Sciences, 1997-present
The Wellcome Trust, 1997-present
Edward N. and Della L. Thome Memorial Foundation Awards Program in Alzheimer’s Disease Drug Discovery Research
Weston Brain Institute Transformational Research Program, Toronto, 2015-present
ZonMw Netherlands Organization for Health Research and Development, 2010-present
Book Publishers
American Psychiatric Press Inc., 1995-present
Cambridge University Press, 1995-present
F.A. Davis Publishers, 1991-present
John Wiley and Sons, 1994-present
Mosby Publishers, 1995-present
Oxford University Press, 1997-present
Swets and Zeitlinger, 1997-present
Internet Sites
WebMD, 2001-present
COLUMNIST
Psychiatric Times- The Aging Brain Column, 1997-present
CONSULTANT FOR DRUG DEVELOPMENT
Hoechst, Marion, Roussel Dementia Advisory Panel, 1997-2002
Eisai, Alzheimer's Disease Program, 1998-present
Bayer, Dementia Advisory Panel, 1998-2003
Novartis Neuroscience, 1999-present
Pfizer Alzheimer's Disease Development Program 1999-present
Consultant, Dementia Research, Janssen Pharmaceutica 2000-present
Sention Inc., Dementia Drug Development, 2002-2005
Sanofi-Aventis Alzheimer's Disease, 2005-present
Elan Alzheimer's Disease, 2007-present
HOSPITAL COMMITTEES
Member, Emergency Medical Committee, Butler Hospital, 1991-1996
Member, Executive Committee, Medical Staff Association, Butler Hospital, 1994-2000
Member, Butler Hospital Research Strategic Planning Committee. 2009-2010
UNIVERSITY COMMITTEES
Member, Stanford Medical School Medical Ethics Committee, 1983-1985
Member, Yale Hillel Medical Ethics Study Section, 1986-1991
Member, Brown University Brain Imaging Center Planning Committee, 1994-1996
Associate Director, Brown University Geriatric Neuropsychiatry Research and Treatment Program, 1994-present
Member, Brown University Biomedical Computing Committee, 1995-1998
Member, Brown University Geriatric Psychiatry Fellowship Planning Committee, 1997-present
Member, Brown University Psychiatric Residency Curriculum Committee, 1997-present
Member, Brown University Department of Psychiatry Education Committee, 1997-present
Member, Providence VA/Brown University Geriatric Psychiatry Faculty Search Committee,
1997-2000
Member, Brown University Neurology Residency Education Committee, 1998-present
Member, Brown University Greer Professorship/Director of the Division of Geriatric Medicine Search Committee, 1998 -1999
Member, Brown University Psychiatry Residency Research Track Planning Committee,
1998-present
Member, Brown University Surdna Fellowship Review Committee, 1998-present
Reviewer, Royce Fellowship Committee, 2000-present
Member, Brown MRI Research Facility Executive Committee, 2000-2012
Co-Director, Brown Department of Psychiatry Imaging Core, 2000-present
Member, Brown Medical School Director of Pediatric Neurology Search Committee,
2001-2002
Member-Departments of Psychiatry and Psychology Research Planning Committee, 2002-present
Member-Steering Committee, Brown Cooperative for Translational Brain Research, 2002-present
Member, Department of Clinical Neurosciences Promotions Committee, 2004-present
Member, Search Committee Director of Stroke Service Rhode Island Hospital, 2009-present
Member, Department of Psychiatry Genetics Research Committee, 2009-present
Member, Department of Psychiatry Imaging Research Committee, 2009-present
Member, Department of Psychiatry Chair Search Committee, 2011-present
NATIONAL COMMITTEES
Member, Consultation-Liaison Committee, American Psychiatric Association, 1987-1989
Chairman, Scientific Program Committee, American Neuropsychiatric Association, 1993-1995
President, American Neuropsychiatric Association, 1997-1998
Member, Old-Old Depression Research Consortium, 1998-present
Member, International Neuropsychological Society Scientific Program Committee, 2003-4
Member, Data Safety Monitoring Board, Rasgaline for Treatment of Mild-Moderate Alzheimer’s Disease, Eisai Inc., 2004-2005.
Member, Institute for the Study of Aging Working Group on Guidelines for the Treatment of Alzheimer’s Disease in the Managed Care Setting in New York City on October 10, 2005
Member, Medical Advisory Board. Alzheimer’s Federation of America, 2004-present
Member, Guidelines for the Treatment of Dementia Panel, American Academy of Neurology, 2006-present
Member, Scientific Advisory Board. CADASIL: Together We Have Hope Foundation, 2006-present
Co-chair, Safety Evaluation Committee, Merck amyloid vaccine trial V950-001, 2007-present
Member, Steering Committee ELND005-AD201–A Phase II, Double Blind, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of Oral ELND005 in Mild to Moderate Alzheimer’s Disease. 2008-present.
Chair, Steering Committee, of the phase III, multicenter, randomized, double-blind, placebo-controlled trial of bapineuzumab (AAB-001, ELN115727) in patients with mild-moderate Alzheimer’s disease who are apolipoprotein Ee4 carriers and non-carriers.
Research Against Alzheimer’s, member, 2012-present
Member, AI Coverage with Evidence Development Executive and Scientific Committees, 2013-present
Member, Alzheimer’s Disease Discovery Foundation Advisory Panel on Combination Therapy in Alzheimer’s Disease. 2015-present
Member, Global Alzheimer’s Platform Site Leadership Committee, 2015-present
Member, Global Alzheimer’s Platform Site Activation Committee, 2015-present
Member, Alzheimer’s Disease Discovery Foundation Scientific Advisory Board, 2015-present
Member, NIA-funded Ante-Amyloid in Asymptomatic Alzheimer’s Disease Compound Selection Committee, 2017-present
INTERNATIONAL COMMITTEES
Member, Advisory Panel, Third International Neuropsychiatry Congress Scientific Program Committee, Kyoto, Japan, 2000, 1997-2000
Member, Eisai/Pfizer International Advisory Board on Vascular Dementia, 2001-present
Member, Executive Committee International Neuropsychiatry Congress Planning Committee,
1998-present
Co Chair: International working group to revise the NINDS vascular dementia criteria for the International Society for Vascular Behavioral and Cognitive Disorders, 2002-present
Member, International Stroke Society to Develop an Organizing World Federation Committee for Stroke and Vascular Dementia, 2002-present
Member, Vascular Risk Factors and Dementia: Raising Risk Awareness Study Group, Madrid, Spain, October, 2005.
Member, International CADASIL Study Steering Committee, Eisai, 2005-present
Member, Scientific Program Committee, 3rd Congress of the International Society for Vascular Behavioral and Cognitive Disorders, 2006-present
Member, Dimebon phase 3 Data Monitoring Committee, 2008-present
Member, Steering Committee Alzheimer’s Disease Neuroimaging Initiative, 2004-present.
Member, Steering Committee, Dominantly Inherited Alzheimer’s Network, 2007-present.
Member, International Hydrocephalus Society Neuropsychology Consensus Panel, 2009-present.
Member, Clinical Trials Committee, Dominantly Inherited Alzheimer’s Network, 2009-present.
Member, Scientific Program Committee, 6th Clinical Trials in Alzheimer’s Disease Annual Meeting, 2013-present
Member, EU/US Task Force on Alzheimer’s Trials: Outcome Measures, 2014-present
Faculty member, 2015 Margolese National Brain and Heart Disorders Prizes, 2015-present
Alzheimer’s Association CSF Biomarkers Appropriate Use Criteria Work Group, 2016-present
MEMBERSHIP IN SOCIETIES
2013-present New York Academy of Sciences
2004-present American Neurological Association
2008-present International Society to Advance Alzheimer Research and Treatment
1988-present American Neuropsychiatric Association
1995-7 Associate Director, 1997-8 President, 1993-5 Chair Scientific Program Committee, Member, Committee on Research
1989-present American Academy of Neurology, Neuroimaging Section, Geriatric Neurology Section Behavioral Neurology Section
1994-2005 Society for Neuroscience
1994-present Behavioral Neurology Society
2003-present International College of Geriatric Psychoneuropharmacology
2002-present International Society for Vascular Behavioral and Cognitive Disorders
2000-present American Association of Geriatric Psychiatry Affiliate Member
2004-present International Psychogeriatrics Association
1987-1997 American Psychiatric Association Consultation - Liaison Committee, 1987-1989
1986-1995 American Medical Association
Teaching (see CV for a complete list of trainees and projects)
Undergraduate Education
Director of an Independent Study Course in neurobehavioral research for undergraduates majoring in neuroscience and biology (B195/196) (1-3 students per semester, includes honors thesis for eligible seniors)
Brown Medical Student Education
Lecturer in the first year Biol3652IMS-II Brain Sciences course
Extended Medical Student Research Elective and Geriatrics Concentration Mentor
Former Director of the second semester, first year course. The Human Brain and Behavior (Biomed 370)
Post-graduate Medical Education
Director of the Alzheimer’s Disease Research Fellowship
Director of the Fellowship in Neurodegenerative Disorders
Supervisor, Geriatric Psychiatry Fellowship Program
Vascular Service Attending - Rhode Island Hospital
Director Emeritus of the American Board of Psychiatry and Neurology/ACGME-Approved 855-43-44-005 Brown University Combined Residency Training Program in Neurology and Psychiatry
NIA ZAG1 FAS-5 J1 Institutional National Research Service Award
Dementia Research Fellowship T-32 (Paul Malloy, PI) 2003-2008, co-PI with Richard Besdine
